CN103142577A - Salvianolic acid A composition and application thereof to medicine preparation - Google Patents

Salvianolic acid A composition and application thereof to medicine preparation Download PDF

Info

Publication number
CN103142577A
CN103142577A CN2012104872556A CN201210487255A CN103142577A CN 103142577 A CN103142577 A CN 103142577A CN 2012104872556 A CN2012104872556 A CN 2012104872556A CN 201210487255 A CN201210487255 A CN 201210487255A CN 103142577 A CN103142577 A CN 103142577A
Authority
CN
China
Prior art keywords
salvianolic acid
acid
compositions
purposes
myocardial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012104872556A
Other languages
Chinese (zh)
Other versions
CN103142577B (en
Inventor
蔡元魁
欧阳婷
李志勇
程帆
张功俊
王章伟
汤新乾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Qingfeng Pharmaceutical Co., Ltd.
Original Assignee
陈飞虹
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈飞虹 filed Critical 陈飞虹
Priority to CN201210487255.6A priority Critical patent/CN103142577B/en
Publication of CN103142577A publication Critical patent/CN103142577A/en
Application granted granted Critical
Publication of CN103142577B publication Critical patent/CN103142577B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to application of a salvianolic acid A composition to preparation of medicine for preventing and treating ischemic heart disease. The composition comprises by weight 90%-99% of salvianolic acid A, 0.1%-3% of alkannic acid, 0.1%-3% of rosmarinic acid, 0.1%-3% of salvianolic acid B and 0.1%-5% of salvianolic acid C.

Description

A kind of salvianolic acid A compositions and prepare medicinal usage
Technical field
The present invention relates to a kind of salvianolic acid A compositions and prepare medicinal usage.
Technical background
Ischemic heart desease (IHD) is to cause the uneven cardiac damage caused between coronary flow and myocardium demand because coronary artery circulation changes, modal reason is coronary atherosclerosis, coronary artery thrombosis and crown arteriospasm, accounts for 90% left and right of ischemic heart desease.Its common ground is that the imbalance between supply and demand due to oxygen due to deficiency myocardial blood supply causes myocardial ischemia, anoxia, energy metabolism of myocardial is undesired, can not support the heart normal operation, thereby a series of pathophysiological changes and symptom occur, cause angina pectoris attacks, myocardial infarction even occurs and threat to life.According to position, scope and the pathological changes order of severity, the degree of myocardial ischemia of coronary artery pathological changes, clinical minute five classes: asymptomatic type myocardial ischemia, angina pectoris, myocardial infarction type, ischemic cardiomyopathy type, sudden death type.Comparatively common with angina pectoris, myocardial infarction, sudden cardiac death.And these heart diseases that cause because of the arteria coronaria pathological change are referred to as coronary heart disease abbreviation coronary heart disease.Therefore generally said ischemic heart desease mainly refers to coronary heart diseases and angina pectoris.Heart does not have " oxygen warehouse ", relies on myocardial blood flow fully, so once ischemia can cause anoxia at once.Oxygen is the movable requisite material of myocardial cell, and normal myocardium cellular uptake blood oxygen content reaches 65～75%, and other is organized and only absorbs 10～25%.The direct result of myocardial ischemia is that the myocardial cell aerobic metabolism weakens, and production capacity reduces, and essential energy supply deficiency while making cardiomotility causes that angina pectoris, arrhythmia, cardiac function descend.Simultaneously, the refuse of metabolism can not be removed effectively in time, easily has a negative impact.Ischemia, anoxia, lack energy, finally can affect the contractile function of heart.If have 20%～25% cardiac muscle to stop shrinking, usually there will be left chamber function exhaustion; If have the cardiac muscle more than 40% not shrink, just have the exhaustion of severe cardiac pump function.If this situation occurs suddenly, just there will be breakneck cardiogenic shock.Acute myocardial infarction is just normal relevant to this situation.Myocardial ischemia also can damage diastolic function.Shrink bad and diastole is bad combines, can cause that complicated substance metabolism is disorderly and myocardial electrical activity is not normal.
Therefore improve the cardiovascular function, increase the consumption of myocardium blood supply oxygen supply, reduction oxygen, improve myocardial metabolism, allevating angina pectoris, reducing myocardial infarction area is the main purpose of Drug therapy.The treatment ischemic heart desease mainly comprises Drug therapy and the operative treatments such as intervention (PICA) or bridging at present.Generally use the nitric acid lipid drug during angina pectoris attacks, as the sublingual administration nitroglycerin, rapid-action, but can only be for emergency, relief of symptoms, can not fundamentally treat myocardial ischemia.The catabasis medication comprises nitrate esters, Statins, ACEI, beta-blocker, calcium ion antagonist, Thrombolytic Drugs (urokinase, streptokinase etc.) and Chinese medicine etc.Energy metabolism impairment be myocardium damaged wound make one of reason element, in recent years, regulating energy metabolism of myocardial by optimization, to bring into play the short metabolism class medicine of an antianginal class also quite concerned, is expected to become new class treatment or an ancillary drug.And take at present mainly the arteria coronaria revascularization, recover the ischemic heart desease Primary Care method that blood perfusion is principle as early as possible, also have very important risk: zoopery and clinical research are found, recovery along with blood fortune, some impaired myocardial cell function and structural deterioration increases the weight of on the contrary, myocardial ischemia reperfusion injury (myocardial ischemia reperfusion injury, MIRI) occurs.Reperfusion injury is after myocardial ischemia, perfusion is early stage again, response to oxidative stress causes in cardiac muscle producing a large amount of oxygen-derived free radicals, superoxide anion, accelerate apoptosis of cardiac muscle and necrosis together with factors such as calcium overloads in cell and mitochondrion, make myocardial infarct size expansion, cardiac function worsen rapidly.Clinical manifestation be inaccessible coronary artery more logical and infarcted region hemoperfusion rebuild after in a period of time, blood pressure rapid drawdown, cardiac insufficiency, arrhythmia a series of phenomenons that sb.'s illness took a turn for the worse such as even die suddenly occur in some patients.All there is the reperfusion injury problem after as logical again as thrombolysis in myocardial infarction in clinical practice, after coronary artery bypass grafting, heart transplantation, sudden cardiac arrest cardiac resuccitation, after open-heart surgery etc.How to accomplish both to have guaranteed to recover as early as possible the blood flow of ischemic tissue, alleviate again the generation of even removing reperfusion injury and just become the important topic in another coronary heart disease control.
World Health Organization (WHO) gives a warning in " global disease burden " report, and cardiovascular system diseases has become the underlying cause of death of global range.Statistical data shows, the 2000 ten thousand people acute cardiovascular disease that happens suddenly often is close in the whole world, cause death toll account for the whole world dead more than 30%, wherein 43% die from coronary heart disease.On Regional Distribution, the cardiovascular disease death more than 80% occurs in low middle income country.It is reported, the U.S. approximately has 45～500,000 people to die from sudden cardiac death every year, and wherein with ischemic heart desease (coronary heart disease), accounts for more than 80% of reason of sudden death.Nearly decades, Incidence of CHD increases year by year in China, in all kinds of heart disease, ranks first at present.Within 2010, the China national statistical data shows, China dies from cardiovascular disease over 40% people.Effective control of coronary heart disease has become the major global public health problem can not be ignored, the development of this class diseases prevention and treatment medicine is listed in the key content of China's Eleventh Five-Year Plan, the great special item of " 12 " original new drug continuously, and will become the drug categories of a very long time primary study from now on, great social meaning and economic worth will be arranged.
The dry root and rhizome that Radix Salviae Miltiorrhizae is Labiatae salvia Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bunge, have the effect of blood circulation promoting and blood stasis dispelling, removing heat from blood eliminating carbuncle and nourishing blood to tranquillize the mind.Radix Salviae Miltiorrhizae, as the medicine of traditional Chinese medical science tradition blood circulation promoting and blood stasis dispelling, because of determined curative effect, starts to be widely used in clinical departments from the seventies, becomes one of the widest at most medicine of clinical practice.Because having the pharmacological actions such as the microcirculation of improvement, coronary artery dilating, inhibition thrombosis, anticoagulant, protection ischemic myocardium, the clinical practice in modern age of its preparation is mainly used in ischemic cardiac, cerebrovascular disease.The Chinese patent medicine of the treatment myocardial ischemia containing Radix Salviae Miltiorrhizae commonly used has: Radix Salviae Miltiorrhizae Tabellae, FUFANG DANSHEN PIAN, the heart can relax, arteria coronaria is peaceful etc.; Include coronary artery dilator, increased coronary flow, reduced blood viscosity and blood clotting, anticoagulant, protection ischemic myocardium and improved the pharmacological action such as microcirculation.Be applicable to the thoracic obstruction patient of Blood stasis and angina pectoris acute attack etc.
The effective substance of Radix Salviae Miltiorrhizae is water-soluble phenolic compounds wherein, comprise salvianolic acid A-G, rosmarinic acid and methyl ester thereof, danshensu, protocatechualdehyde, protocatechuic acid etc., take antioxidation, anticoagulant and antiinflammatory as characteristics, there is protection vascular endotheliocyte, blood fat reducing, rising HDL, anticoagulant, activation fibrinolytic simultaneously, suppress the pharmacological action of the multiple beneficial such as Fibrinogen is synthetic, chelating calcium iron ion; Wherein the strongest with the salvianolic acid A activity.Salvianolic acid A can improve the rear rat heart muscle H9c2 cell survival rate of damage, inhibited apoptosis, and very strong antioxidation is arranged, can obviously alleviate mitochondrial injury.Therefore salvianolic acid A can have protective effect to ischemic myocardium by alleviating the mechanism such as apoptosis of cardiac muscle, raising antioxidant ability of organism and protection myocardial mitochondria.Salvianolic acid A also has significant protective effect to myocardial ischemia reperfusion injury; and effect be better than salvianolic acid B (Lin Zhirong etc. the comparative study [D] of salvianolic acid A and salvianolic acid B resisting myocardial ischemia-reperfusion injury. time treasure's traditional Chinese medical science traditional Chinese medicines; 2011,22 (2): 412-424).
But the natural content of salvianolic acid A extremely low (0.01-0.06% that is about red rooted salvia), make the crude drug high cost, the separation and purification difficulty is excessive, is seriously restricting the R and D of medicine, becomes the bottleneck of its industrialization.In addition, in prior art, also have experiment confirmation salvianolic acid B to degrade and can change into salvianolic acid A by ester hydrolysis decarboxylation and chroman ring ring-opening reaction, but the conversion process of above-mentioned prior art is uncontrollable, conversion byproducts is many, and the productive rate of principal product salvianolic acid A is lower.
Although also there are some patent documentations to propose to attempt to overcome the defect existed in prior art in prior art, but be only all that simple trial heats up, changes pH value or improves concentration that transforms front pressure differential self etc., without any a patent or prior art deeply, study conversion reaction all sidedly and all comprise which major influence factors, how synergism exerts an influence to the salvianolic acid A productive rate jointly each other as the concentration that transforms front pressure differential self, pH value, temperature, time etc. more without any a patent or prior art, to propose these factors.
On this basis, seldom there are other inventors or prior art to propose to attempt adding catalyst in conversion so that reaction is more abundant, having related to the related content that adopts catalyst to be transformed in currently available technology exists only in two parts of patent application documents submitting in same day of on April 6th, 2010, these two parts of patent application documents are respectively that application number is 2010101436787, patent application and application number that denomination of invention is " a kind of catalyzed conversion salvianolic acid B prepares the method for salvianolic acid A " are 2010101436876, the patent application that denomination of invention is " a kind of method that preliminary purification salvianolic acid B transforms raw material ".In the description of these two parts of patent applications, although disclose the technology contents that the catalyzed conversion salvianolic acid B prepares salvianolic acid A, its catalyst is carbamide, the mol ratio of carbamide and salvianolic acid B is (0.4～0.6): 1, require consume and add carbamide very high, so production cost is very high.And, in above-mentioned two parts of patent application documents, do not pay close attention to too the collaborative impact that the salvianolic acid A productive rate is produced of pH value and other correlative factors.Moreover it transforms raw material be the radix Salviae Miltiorrhizae water extract through the co-chromatography preliminary purification, salvianolic acid B >=50% wherein, this all has relatively high expectations to purity and purifying technique of transforming raw material, and technique is complexity comparatively also, has further increased production cost.More crucial, although claim " the directed conversion ratio of the salvianolic acid A salvianolic acid B that uses this method to prepare >=10%, even reach 60% " in its application documents.But because in fact carbamide do not have open loop, dehydration, decarboxylation, the ester effect is only arranged into, and therefore, its conversion ratio does not reach 60% at all, and the conversion ratio in the specific embodiment of this application file is only up to 53%, and the conversion ratio of a plurality of embodiment is only 10%, 20% and 30%.Still there is a big difference in the requirement of this and actual industrialization.
Summary of the invention
The above-mentioned defect existed for overcoming prior art, the invention provides a kind of salvianolic acid A compositions for the preparation of the purposes that prevents and/or treats the ischemic heart medicine.
The invention provides the purposes of a kind of salvianolic acid A compositions for the preparation of prevention and treatment ischemic heart medicine, compositions goes out salvianolic acid A, alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C composition; Wherein
The molecular formula of described salvianolic acid A: C 26h 22o 10, molecular weight: 494.45, structure is as follows:
Figure BSA00000811649200041
The molecular formula of described alkannic acid: C 27h 22o 12, molecular weight: 538.46, structure is as follows:
Figure BSA00000811649200051
The molecular formula of described rosmarinic acid: C 18h 16o 8, molecular weight: 360.31, structure is as follows:
Figure BSA00000811649200052
The molecular formula of described salvianolic acid B: C 36h 30o 16, molecular weight: 718.61, structure is as follows:
The molecular formula of described salvianolic acid C: C 26h 20o 10, molecular weight: 492.43, structure is as follows:
Figure BSA00000811649200054
Wherein said compositions is to be made by following weight proportion: salvianolic acid A 90%～99%, alkannic acid 0.1%～3%, rosmarinic acid 0.1%～3%, salvianolic acid B 0.1%～3%, salvianolic acid C 0.1%～5%.
Preferably, wherein said compositions is to be made by following weight proportion: salvianolic acid A 93%～98%, alkannic acid 0.1%～2.0%, rosmarinic acid 0.1%～2.0%, salvianolic acid B 0.1%～2.0%, salvianolic acid C 0.1%～3%.
Preferably, wherein said compositions is to be made by following weight proportion: salvianolic acid A 94%～97%, alkannic acid 0.1%～1.5%, rosmarinic acid 0.1%～1.5%, salvianolic acid B 0.1%～1.5%, salvianolic acid C 0.1%～2.0%.
Preferably, wherein said compositions is to be made by following weight proportion: salvianolic acid A 95%～96%, alkannic acid 0.1%～1.2%, rosmarinic acid 0.1%～1.2%, salvianolic acid B 0.1%～1.2%, salvianolic acid C 0.1%～1.5%.
Preferably, described compositions adopts following steps to prepare:
(1) extract: Radix Salviae Miltiorrhizae water or alcoholic solution extract and obtain aqueous extract or alcohol extract;
(2) transform: the extracting solution that step (1) is obtained, adjust pH to 3.5～6.5, add the catalyst that molar percentage is 0.1%～3.0%, 100～140 ℃ of heating 1～6 hour;
(3) purification:
A. solution step (2) obtained, adjust pH to 2.5～4.5, centrifugal, and supernatant separates through nonpolar or low pole macroporous resin column chromatography, after washing with water, uses the eluant eluting, and high performance liquid chromatogram detects salvianolic acid A, collects the eluent that contains salvianolic acid A;
B. sephadex lh-20 or ODS-C18 or the separation of polyamide chromatography post for eluent step a obtained, use the eluant eluting, and high performance liquid chromatogram detects salvianolic acid A, collects the eluent that contains salvianolic acid A;
C. eluent step b obtained is adjusted pH to 2.0～4.0, through organic solvent extraction, and the Separation of Organic phase;
D. solution step c obtained separates with silica gel column chromatography, uses the eluant eluting, and high performance liquid chromatogram detects salvianolic acid A, collects the eluent that contains salvianolic acid A;
(4) drying: the eluent that steps d is obtained, the reclaim under reduced pressure eluant, then be dissolved in water, with vacuum drying, spray drying or microwave vacuum drying, obtain described salvianolic acid A compositions.
Preferably, wherein the water extracting method described in step (1) is: get red rooted salvia, be cut into decoction pieces or be ground into diameter 2mm granule, add 3～15 times of water gagings at every turn and extract, extract altogether 1～3 time, extract 1～4 hour at every turn; Extracting solution is evaporated to relative density 1.10～1.25 (60 ℃), add ethanol to make containing the alcohol amount 30%～80%, centrifugal, the supernatant decompression recycling ethanol also is concentrated into without the alcohol flavor, described water extraction adopts decoction to extract or 45～95 ℃ of water temperature lixiviates are got, stir with 10～50 rev/mins of speed simultaneously, obtain Radix Salviae Miltiorrhizae extract.
Preferably, wherein the alcohol extraction method described in step (1) is: get red rooted salvia, be cut into decoction pieces or be ground into diameter 2mm granule, add 3～15 times of amount 30%～60% alcohol reflux at every turn, extract 1～4 hour at every turn, extract altogether 1～3 time; Decompression recycling ethanol, obtain Radix Salviae Miltiorrhizae extract.
Preferably, wherein in the extracting solution in step (1) salvianolic acid B concentration be 1mg/ml～30mg/ml or be diluted with water to 1mg/ml～30mg/ml.
Preferably, wherein in extracting solution salvianolic acid B concentration be 5mg/ml～20mg/ml or be diluted with water to 5mg/ml～20mg/ml.
Preferably, wherein the catalyst in step (2) is one or more in iron chloride, ruthenium trichloride, aluminum chloride, zinc chloride, Palladous chloride., and the molar percentage of catalyst and salvianolic acid B is 0.1%～3.0%.
Preferably, wherein the molar percentage of catalyst and salvianolic acid B is 0.5%～2.0%.
Preferably, wherein macroporous resin column described in step a is HPD-80, HPD-100, HPD-100B, HPD-200A, HPD-300, HPD-450, HPD-722, HPD-826, ADS-5, ADS-8, ADS-21 or D101, AB-8; The water that described eluant is water and different proportion and ethanol, and first water, 10～40% ethanol elutions, then use 20～60% ethanol elutions, high performance liquid chromatogram detects salvianolic acid A, collects and contains the salvianolic acid A part, and eluent is concentrated into without the alcohol flavor.
Preferably, water and ethanol that wherein the described eluant in step b is water and different proportion, and first water, 20～60% alcoholic solution eluting remove impurity, use again 40～90% alcoholic solution eluting, high performance liquid chromatogram detects salvianolic acid A, collects and contains the salvianolic acid A part, and eluent is concentrated into without the alcohol flavor.
Preferably, wherein the organic solvent described in step c is t-butyl methyl ether, methyl acetate, ethyl acetate, butyl acetate or Ethyl formate.
Preferably, the two-phase solvent that wherein eluant described in steps d is petroleum ether, pentane, normal heptane, ethyl acetate, methyl acetate, Ethyl formate, t-butyl methyl ether composition.
Preferably, the temperature of microwave vacuum drying: 20-100 ℃ described in step (4) wherein, return difference temperature 1-5 ℃, more than vacuum-0.07Mpa, microwave power 1-100KW, dry 10-200 minute.
Preferably, vacuum drying temperature described in step (4) wherein: 50 ℃～90 ℃, more than vacuum-0.07Mpa, power: 1～60KW, dry 2～20 hours.
Preferably, spray-dired intake air temperature described in step (4) wherein: 150 ℃～350 ℃, the air outlet temperature: 70 ℃～95 ℃, spray velocity: 1～300ml/min.
Preferably, wherein pH adjusting agent is phosphoric acid, hydrochloric acid, sulphuric acid or acetic acid.
Preferably, described compositions adopts the high effective liquid chromatography for measuring salvianolic acid A, alkannic acid, and rosmarinic acid, salvianolic acid B, salvianolic acid C content, condition determination is as follows:
Take octadecylsilane chemically bonded silica as filler;
Detect wavelength 286nm; Flow velocity 1.0ml/min; 30 ℃ of column temperatures;
Theoretical cam curve should be not less than 10000 by salvianolic acid A;
The preparation precision of reference substance solution takes salvianolic acid A, alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C reference substance in right amount to volumetric flask, adds methanol and makes the mixing reference substance solution;
The preparation of need testing solution: precision takes sample 10mg in the 100ml volumetric flask, adds dissolve with methanol and shakes up, and be diluted to scale, obtains;
Eluting be take methanol as mobile phase A, take 0.1～0.5% phosphoric acid as Mobile phase B, by following condition, carries out gradient elution, moves 60 minutes;
In the time of 0～10 minute, the ratio of methanol is down to 60% by 30% ratio that rises to 40%, 0.1～0.5% phosphate aqueous solution by 70%;
In the time of 10～30 minutes, the ratio of methanol is down to 45% by 40% ratio that rises to 55%, 0.1～0.5% phosphate aqueous solution by 50%;
In the time of 30～60 minutes, the ratio of methanol is down to 20% by 55% ratio that rises to 80%, 0.1～0.5% phosphate aqueous solution by 45%.
Algoscopy: the accurate absorption mixed reference substance solution and each 10 μ l of need testing solution respectively, and the injection liquid chromatography, measure, and calculates the content of salvianolic acid A, alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C.
Preferably, the wherein said medicine for prevention and treatment ischemic heart desease can be used for treating one or more of following disease: coronary heart diseases and angina pectoris, ischemic cardiomyopathy, myocardial infarction, myocardial ischemia apoplexy, acute coronary syndrome, coronary stricture, myocardial ischemia reperfusion injury, atherosclerosis.
Preferably, wherein said salvianolic acid A compositions is for improving the hemodynamic purposes of Ischemic Heart.
Preferably, wherein said salvianolic acid A compositions is for improving the purposes of ischemic heart cardiac function.
Preferably, wherein said salvianolic acid A compositions is for increasing the purposes of the coronary flow of ischemic heart.
Preferably, wherein said salvianolic acid A compositions is for reducing the purposes of ischemic heart myocardial infarct size.
Preferably, wherein said salvianolic acid A compositions is for dwindling the purposes of myocardial ischemia scope.
Preferably, wherein said salvianolic acid A compositions is for alleviating the purposes of degree of myocardial ischemia.
Preferably, wherein said salvianolic acid A compositions is regulated the purposes of Enzyme Activities for the protection of the myocardial cell membrane structure.
Preferably, wherein said salvianolic acid A compositions is for suppressing the purposes of ischemic myocardial tissue inflammatory reaction.
Preferably, wherein said salvianolic acid A compositions is for the protection of the purposes of myocardial mitochondria damage.
Preferably, wherein said salvianolic acid A compositions is for improving the purposes of myocardial metabolism.
Preferably, wherein said salvianolic acid A compositions comprises for improving one or more of following myocardial metabolism for the purposes of improving myocardial metabolism: myocardium radical metabolism, fatty acid metabolism, energy metabolism.
Preferably, wherein said salvianolic acid A compositions is for reducing the purposes of myocardial oxygen consumption.
Preferably, wherein said salvianolic acid A compositions is for improving hemorheological purposes.
Preferably, wherein said salvianolic acid A compositions is for suppressing thrombotic purposes.
The present invention is by the extraction to Radix Salviae Miltiorrhizae, transform, purification, drying process, obtained take salvianolic acid A as main compositions: through screening and the optimization of system, at first relatively extraction solvent and the extracting method of initiation material salvianolic acid B have been determined, because the salvianolic acid B water solublity is better, employing water extraction or low concentration alcohol extraction have been determined, again because the salvianolic acid B heat stability is poor, determined that employing hot water warm macerating extracts and adds the stirring extracting method, or use the low-concentration ethanol reflux, extract, make to extract solubility lower than 100 ℃, keep salvianolic acid B not to be destroyed, optimum solvent consumption and extraction time have been determined by orthogonal experiment, obtained adapting to the salvianolic acid B optimum extraction process of suitability for industrialized production.
The present invention is compared with the prior art and shows: the direct extraction of the red rooted salvia conversion that can be fed intake for initiation material, do not need salvianolic acid B is carried out being transformed after purification again, be in catalytic conversion reaction of the present invention, the reaction raw materials salvianolic acid B does not need high-purity, does not for example need the purity of salvianolic acid B >=50%.It is generally acknowledged that reaction raw materials is more pure better, yet, in catalytic conversion reaction of the present invention, the purity of salvianolic acid B height is on the not impact of conversion reaction effect.On the contrary, not only produce a large amount of impurity during salvianolic acid B purity>50%, and do not improve conversion ratio, therefore, the present invention has obtained unforeseeable technique effect.
Moreover the present invention by experiment repeatedly relatively, has at first determined that factor that salvianolic acid A compositions productive rate is produced to material impact is as the concentration that transforms front pressure differential self, pH value, temperature, time etc.On this basis, by paying concentration and other correlated conditions that a large amount of time, material and energy tests repeatedly to temperature, pH value, time, salvianolic acid B, be studied again, and these factors each other how synergism with the salvianolic acid A productive rate is exerted an influence, thereby determined that salvianolic acid B transforms the optimum temperature of the needs control of salvianolic acid A, pH value, time etc., and the salvianolic acid B initial concentration is controlled to 1mg/ml～30mg/ml, thereby make salvianolic acid A compositions conversion ratio of the present invention more obviously be better than other conversion conditions.In chemical reaction, the purity of reactant usually affects the effect of reacting with concentration.Generally reactant is had to concentration requirement, and think that the high specific concentration of concentration hangs down.In catalytic conversion reaction of the present invention, the concentration of salvianolic acid B height is on the not impact of conversion reaction effect.On the contrary, it is not more high better to experimental results show that containing the concentration of salvianolic acid B in the salvianolic acid B aqueous solution, and the above concentration conversion ratio of 30mg/ml is low on the contrary, and effect is poorer.Therefore, the present invention, aspect cost-saving and production cycle, has obtained unforeseeable technique effect, creative.In the situation that prior art does not provide any technology enlightenment, if only deduction theoretically of those skilled in the art is impossible draw under above-mentioned each conditional parameter the sour B of pellet is changed into to the conclusion that salvianolic acid A has better changing effect.
What is more important, the present invention passes through performing creative labour, discovery zinc chloride etc. can significantly improve as catalyst the conversion ratio that salvianolic acid B transforms salvianolic acid A, reaching that conversion ratio is highly stable approaches 60%, most cases can surpass 60%, this is all impossible in any one prior art in the past, therefore, has obtained unforeseeable technique effect.
Because salvianolic acid A content is lower, the large raising of salvianolic acid A content after transforming, but also containing large aobvious impurity, therefore, selected respectively low pole and nonpolar macroporous adsorption resin to carry out crude separation, select again polyamide etc., solvent extraction, silica gel to separate, and various flows part is measured, after removing the impurity part, salvianolic acid A content is brought up to 80% from 10% left and right, to 90%, to 93%, to 96%.
Further, when significantly improving conversion ratio, the present invention is by being suitable for the purification step of actual industry application, especially by after the steps such as a series of separation, eluting processing, do not adopt traditional normal temperature drying, but adopt vacuum drying, spray drying, microwave vacuum drying, thereby thoroughly overcome, baking temperature was too high in the past, drying time is long, the large defect to the destruction of salvianolic acid A; And sublimation drying is long, the defects such as organic residue is large in the salvianolic acid A compositions of the high and lyophilization gained of cost.
In addition, the present invention can also mix low concentration with the salvianolic acid B of high concentration, only need be made into suitable initial conversion concentration and get final product, and can reach the purpose that changes into salvianolic acid A equally.Therefore, the preparation technology of this conversion raw material is very simple, and production cost also is very suitable for the application in actual industry when reducing.
In salvianolic acid A compositions of the present invention, except main, contain salvianolic acid A, also containing a small amount of salvianolic acid B, alkannic acid, rosmarinic acid, salvianolic acid C; Salvianolic acid A is by removing free radical, alleviates mobility and the permeability that the membrane lipid peroxidating causes and changes, and stops the spilling of abnormal penetrating and enzyme of ion, thereby reduced the damage caused due to myocardial ischemia-reperfusion, and myocardial ischemia is had to protective effect.But salvianolic acid A compositions dose dependent ground suppresses the platelet aggregation that adenosine diphosphate (ADP), thrombin, arachidonic acid, collagen or U46619 induce, reduce cAMP level in platelet, and the expression and the Fibrinogen combination that reduce the P-selectin that ADP causes, thereby the platelet leukocyte recruitment that stops ADP to cause, be formed with preventive and therapeutic effect to atherosclerosis and thromboembolism;
Salvianolic acid B in the salvianolic acid A compositions is the main effective ingredient of Radix Salviae Miltiorrhizae and preparation Radix Salviae Miltiorrhizae Injection thereof, XIANGDAN ZHUSHEYE, and the same with the salvianolic acid A compositions have protective effect to myocardial ischemia, and atherosclerosis and thromboembolism are formed with to preventive and therapeutic effect; Salvianolic acid B can effectively reduce the infarct scope of experimental myocardial infarction rat, increases fibroblast and capillary vessel number in infarct; Can reduce the left chamber diastole art phase of Model of Acute Myocardial Ischemia rat and press, the rising left indoor pressure is maximum to rise and fall off rate, effect that heavy dose of application is shunk left chamber and diastolic function all is significantly increased; To Rabbit Myocardium anoxia one reoxygenation injury model, salvianolic acid B has the negativity frequency, increases the effect of creatine kinase, lactic dehydrogenase enzyme level in coronary flow and reduction coronary outflow, can alleviate myocardial cell injury.But salvianolic acid B dose dependent ground reduces H 2o 2due to endotheliocyte LDH leak outside and MDA generates, and improve NO and discharge, can also effectively suppress H 2o 2exist lower CD54 express and increase the neutrophil adhesion rate, show that salvianolic acid B has the H of alleviating 2o 2due to the oxidative damage of endotheliocyte, reduce the Surface of Vascular Endothelial Cells Expression of Cell Adhesion Molecules and suppress the effect of neutrophil adhesion, and think that this is the mechanism of action of salvianolic acid B resisting myocardial ischemia/reperfusion injury; Alkannic acid, rosmarinic acid, salvianolic acid C effect and salvianolic acid A are roughly the same, stronger antioxidation is all arranged, can remove oxygen-derived free radicals, suppress lipid peroxidation, its action intensity is higher than vitamin C, vitamin E, is one of natural product that at present known antioxidation is the strongest.Rosmarinic acid also contributes to prevent that the cell that free radical causes is impaired, has therefore reduced cancer and arteriosclerotic risk.
Alkannic acid in the salvianolic acid A compositions suppresses propagation and the migration of vascular smooth muscle cell in addition, and prevention of arterial is atherosis, angiostenosis and vascellum endometrial hyperplasia, has vasodilative effect.Can suppress uric acid and cross the formation of ultra-oxygen anion free radical, the generation of inhibition peroxide, the effect of antiinflammatory and uric acid resisting is arranged.The external effect that can suppress metakentrin release.
Thereby the salvianolic acid C in the salvianolic acid A compositions is also apoptosis-induced by suppressing the retardance of tubulin polymerization inducing cell mitosis, has anti-tumour cell proliferative activity.
There is common ischemic myocardial protection effect after salvianolic acid A in the salvianolic acid A compositions, salvianolic acid B, alkannic acid, rosmarinic acid, salvianolic acid C combination, reduced the damage caused due to myocardial ischemia-reperfusion.What atherosclerosis and thromboembolism were formed has a preventive and therapeutic effect, and use effect is stronger separately than salvianolic acid A monomeric compound to make it, also have simultaneously antiinflammatory and uric acid resisting effect, reduced cancer and arteriosclerotic risk.
On the other hand, the present invention also provide its for prevention and or the purposes for the treatment of ischemic heart medicine, and by experimental results demonstrate:
Test Data Comparison through sky known, model group ischemia-reperfusion 60min, CBF ,+dp/dt max,-dp/dt maxobviously descend, LVEDP significantly increases.With model group, compare, positive drug group, the high, medium and low dosage group of salvianolic acid A compositions, salvianolic acid A monomeric compound group These parameters all have clear improvement, and can suppress the maximum climbing speed decline of coronary flow minimizing, the rising of left chamber diastolic pressure, left indoor pressure, the maximum fall off rate decline of left indoor pressure that ischemia-reperfusion causes.And salvianolic acid A compositions group high dose group is suitable with positive drug group effect, effect is better than same dosage salvianolic acid A monomeric compound group.Experimental result shows that the salvianolic acid A compositions can alleviate isolated rat heart ischemical reperfusion injury degree, and prompting salvianolic acid A compositions can obviously be improved coronary flow, improve systolic and diastolic function, the cardioprotection ischemical reperfusion injury of isolated heart aorta diastolic function and damaged myocardium.
Through known to the contrast of the experimental data of rats with myocardial ischemia electrocardio and effect of heart function, following coronary artery occlusion causes the long-term myocardial infarction and ischemia model Rat Ecg of rat ST section and significantly improves, its HR, arterial pressure, LVSP ,+dp/dt max,-dp/dt maxall significantly descend, model group rat heart muscle contractile function obviously reduces, and after intravenously administrable 7d, each medicine group rat ST section obviously descends; The indices integrated display, with the middle and high dosage of salvianolic acid A compositions, the electrocardio of long-term rats with myocardial ischemia and parameters of left ventricular function are improved to effect in each medicine group the most obvious, prompting salvianolic acid A compositions can reduce rats with myocardial ischemia ST section rising, improve heart rate, increase its arterial pressure, improve the cardiac muscle contracting power of relaxing, and effect is better than same dosage salvianolic acid A monomeric compound, electrocardio and the cardiac function of rats with myocardial ischemia improved significantly.
Known through the experimental data contrast; the salvianolic acid A compositions can make SOD activity in rats with myocardial ischemia serum increase; suppress the generation of MDA, reduce AST, CK and LDH activity in serum, illustrate that the salvianolic acid A compositions can suppress oxygen-derived free radicals and produce; improve the oxidation resistance of cardiac muscular tissue; the protecting myocardial cell film, reduce overflowing of enzyme, improves myocardium energy supply; reduce ischemia to myocardium degree of injury, thereby play the ischemic myocardial protection effect.
Known through the experimental data contrast, obvious myocardial ischemia infarction appears in myocardial infarction and ischemia model group rat, and infarction size reaches 53% left and right; With model group, compare, after various dose salvianolic acid A compositions drug administration by injection 7d, the myocardial infarct size of rat significantly reduces, and presents certain dose-effect relationship.Less than salvianolic acid A monomeric compound group rat myocardial infarction model scope with dosage salvianolic acid A compositions.Prompting salvianolic acid A compositions can be dwindled myocardial infarct size, alleviates treating myocardial ischemia damage and heart infarction degree, and myocardial ischemia is had to obvious therapeutic action.
Light microscopic and Electronic Speculum results suggest, the salvianolic acid A compositions can obviously be improved the myocardium pathological change of rats with myocardial ischemia, alleviates myocardium pathology damage, can be used for the treatment of ischemic heart desease.And action effect is than more obvious with the salvianolic acid A monomeric compound of dosage.
Observation myocardial ischemia in rats-fill with again the different time myocardial infarct size, model group myocardial ischemia in rats 1.5h, then after pouring into 6h, myocardial infarction is serious, and in recovering perfusion 48h, infarction size progressively increases, the myocardial damage aggravation.Known through the experimental data contrast, with model group, compare, various dose salvianolic acid A compositions can obviously be dwindled myocardial infarct size, alleviate the myocardial ischemia-reperfusion damage, and myocardial infarct size does not enlarge with the Ischemia Reperfusion time lengthening; There is certain agent effect relationship between each dosage group, and be better than same dosage salvianolic acid A monomeric compound.Prompting salvianolic acid A compositions can be dwindled the myocardial infarct size that expeirmental myocardial ischemia pours into rat again, alleviates Myocardial injury degree, and Myocardial Ischemia Reperfusion Injury is had to preventive and therapeutic effect preferably.
Known through the experimental data contrast, rat is at ischemia-reperfusion 24h, the SOD of cardiac muscular tissue, GSH-Px, CAT enzyme are lived and are significantly descended, MDA, XOD enzyme are lived and are significantly raise, the prompting myocardial ischemia in rats-after pouring into again, Peroxidation Product is piled up serious, and myocardial clearance Peroxidation Product ability significantly descends, and Ischemia Reperfusion causes that a large amount of oxygen-derived free radicals generations cause myocardial damage to increase the weight of.Medicine group and model group compare, and the SOD of cardiac muscular tissue, GSH-Px, CAT enzyme are lived and raise in various degree, and MDA, XOD enzyme are lived and reduced in various degree, and salvianolic acid A combines object height, middle dosage group effect is the most obvious.The prompting salvianolic acid A can strengthen myocardial clearance free radical ability, suppresses oxygen-derived free radicals and produces, and strengthens the rat heart muscle oxidation resistance, suppresses Myocardial Ischemia Reperfusion Injury.
Known through the experimental data contrast, after ligation dog coronary artery, 60min is to (be after administration 45min to during 165min after medicine) during 180min after ligation, each medicine group dog epicardial electrogram ST section is raised sum (∑-ST) continuous decrease, with model group, significant difference is more all arranged; After recovering perfusion again, each medicine group ∑-ST and model group significantly reduce.There is a certain amount of effect relationship between each dosage group of salvianolic acid A compositions, in the salvianolic acid A compositions, dosage group ∑-ST fall is suitable with 0.5mg/kg hydrochloride for injection diltiazem group, and the salvianolic acid A compositions descends more obvious than the ∑ with dosage salvianolic acid A monomeric compound group-ST.Prompting salvianolic acid A compositions can alleviate the degree of myocardial ischemia of experiment ischemia-reperfusion dog, and effect is better than same dosage salvianolic acid A monomeric compound.Point out it to damage by Ischemic myocardium, ischemic heart desease is had to good therapeutical effect.
Known through the experimental data contrast, after ligation dog coronary artery, 60min is to (be after administration 45min to during 165min after medicine) during 180min after ligation, each medicine group dog epicardial electrogram N-ST still continues to reduce, and with model group, significant difference is more all arranged; After recovering perfusion again, each medicine group N-ST and model group significantly reduce.There is a certain amount of effect relationship between each dosage group of salvianolic acid A compositions, in the salvianolic acid A compositions, dosage group N-ST slip is suitable with 0.5mg/kg hydrochloride for injection diltiazem group, and the salvianolic acid A compositions reduces obviously than the N-ST with dosage salvianolic acid A monomeric compound group.Prompting salvianolic acid A compositions can reduce the myocardial ischemia scope of experiment ischemia-reperfusion dog, and effect is better than same dosage salvianolic acid A monomeric compound.Point out it to damage by Ischemic myocardium, ischemic heart desease is had to good therapeutical effect.
Known through the experimental data contrast, after model group dog ischemia-reperfusion, myocardial infarction is heavier.Salvianolic acid A compositions, hydrochloride for injection diltiazem, salvianolic acid A monomeric compound all can significantly reduce the experimental dog myocardial infarct size, and, with salvianolic acid A compositions high dose group dog myocardial infarction ratio minimum, in the salvianolic acid A compositions, dosage group myocardial infarct size is less than same dosage salvianolic acid A monomeric compound group.With model group, compare; salvianolic acid A combination object height, middle dosage group can extremely significantly reduce the proportion that infarcted myocardium accounts for heart and ventricle; the proportion that salvianolic acid A compositions low dosage dog myocardial infarction district accounts for heart and ventricle also obviously reduces; prompting salvianolic acid A compositions energy dose dependent ground dwindles the experimental dog myocardial infarct size; energy Ischemic myocardium-reperfusion injury, be used for the treatment of ischemic heart desease.And effect is better than same dosage salvianolic acid A monomeric compound.
Known through experimental data contrast, ligation dog coronary artery forms myocardial ischemia, and after administration, 45min, to 225min (being ligation 60min to 240min) after administration, compares before each medication therapy groups coronary flow and administration, has increased between 25.3%～52.6%; The most remarkable with salvianolic acid A combination object height, middle dosage group, hydrochloride for injection diltiazem group, amplification is respectively 52.6%, 40.2%, 36.7%.In the salvianolic acid A compositions, dosage group amplification is higher than same dosage salvianolic acid A monomeric compound group.Prompting salvianolic acid A compositions can promote collateral circulation open, the coronary flow while increasing myocardial ischemia, thus to resisting myocardial ischemia, the Ischemic myocardium damage, point out it aspect control ischemic heart desease, certain purposes being arranged.
Known through the experimental data contrast, 15min after the administration of salvianolic acid A compositions (being ischemia 30min) can significantly suppress LVEDP rising, inhibition ± dp/dt maxdescend, suppress dog LVW reduction TPR, 45min after administration (after being ischemia 60min) can significantly suppress CO and descend; Be dose dependent; The trend that is better than same dosage salvianolic acid A monomeric compound is arranged.After the administration of prompting salvianolic acid A compositions, can improve myocardial ischemia dog hemodynamic index, the myocardial contraction of Enhancement test dog, improve myocardium systolic and diastolic function, reduce Peripheral resistance, suppress the blood-pumping function that cardiac output reduces, improves heart, improve the myocardial blood supply, improve myocardial ischemia and cardiac function, the performance function of resisting myocardial ischemia.
Known through the experimental data contrast, in myocardial infarction and ischemia model group dog serum, CK, LDH, AST, CK-MB significantly raise, and after the ligation coronary ischemia is described, the dog myocardial mitochondria is destroyed, myocardial cell injury, and myocardium enzyme is released the rising alive of the clear center of hyperamization creatase.Each dosage group of salvianolic acid A compositions and model group relatively, can reduce to some extent after dog myocardial ischemia 4h CK, LDH, AST, CK-MB activity in serum, and be dose dependent; Middle dosage salvianolic acid A compositions group ratio is with dosage salvianolic acid A monomeric compound group more remarkable effect.Illustrate that the salvianolic acid A compositions can stablize myocardial cell membrane, the overflowing of myocardium enzyme during the minimizing treating myocardial ischemia damage, have obvious protective effect to ischemic myocardium.
Known through the experimental data contrast, the model group dog is after ischemia 4h, serum free fatty acid (FFA), lipid peroxide (LPO) significantly raise, after the prompting myocardial ischemia, obstacle appears in the Myocardial Fatty Acids metabolism, the activity that will suppress the glucose oxidase Major Enzymes, thereby the increase myocardial oxygen consumption, enlarge myocardial infarct size.And each dosage group of salvianolic acid A compositions and model group are relatively, can significantly reduce FFA in the myocardial ischemia dog serum, LPO content, and be dose-dependence.Prompting salvianolic acid A compositions can significantly suppress FFA level in serum and raise, and improves the Myocardial Fatty Acids metabolism, reduces the accumulation of lactic acid; increase the production capacity of unit oxygen consumption, reduce myocardial oxygen consumption, thereby improve cardiac function; suppress myocardial infarct size, the Ischemic myocardium damage.
Known through the experimental data contrast, after model group dog myocardial ischemia 4h in serum MDA content significantly raise, SOD, GSH-Px are active significantly to descend, after prompting dog myocardial ischemia, oxygen-derived free radicals generates obviously to be increased, remove the enzyme significantly reduction alive of oxygen-derived free radicals in body, and oxygen-derived free radicals can affect by a series of oxidation reactions normal configuration and the function of cell, aggravation treating myocardial ischemia damage degree.Each dosage group of salvianolic acid A compositions and model group relatively, can significantly reduce the content of MDA in the myocardial ischemia dog serum, make the active obviously enhancing of SOD in serum, GSH-Px simultaneously, and are certain agent effect relationship; Prompting salvianolic acid A compositions can suppress the lipid peroxidation process by certain mechanism, reducing oxygen-derived free radicals generates, simultaneously can improve the endogenous activities of antioxidant enzymes again and alleviate oxygen-derived free radicals to myocardium damage, improving the oxidation resistance of ischemic myocardium and bring into play function of resisting myocardial ischemia.And effect is better than same dosage salvianolic acid A monomeric compound.
Known through the experimental data contrast, the salvianolic acid A compositions of various dose can reduce the aobvious and coefficient of oxygen utilization of myocardial oxygen consumption to some extent, and wherein salvianolic acid A combination object height, middle dosage group ischemia 120min (being 105min after administration) coefficient of oxygen utilization have reduced respectively nearly 20%, 16% before than administration.Illustrate that the salvianolic acid A compositions can reduce myocardial oxygen consumption and coefficient of oxygen utilization, improve the equilibrium of supply and demand of myocardium oxygen, improve ventricular function, the effect of performance protection ischemic myocardium, control myocardial ischemia.
Known through the experimental data contrast, various dose salvianolic acid A compositions can make myocardial ischemia dog blood viscosity, plasma viscosity, packed cell volume and platelet adhesion rate reduce to some extent, obviously reduces fiber protein content in blood plasma; Be certain agent effect trend between each dosage group; Prompting salvianolic acid A compositions can reduce blood viscosity, suppresses platelet adhesion and assembles, and the prevention Intravascular Thrombus forms, and improves myocardial ischemia dog hemorheology, improves microcirculation, can be for preventing and treating ischemic heart desease.
Known through experimental data contrast, the salvianolic acid A compositions of various dose can significantly alleviate that rat suppository is wet, dry weight, and thrombosis is had to obvious inhibitory action; Be certain dose-effect relationship between each dosage group, and inhibition is better than same dosage salvianolic acid A monomeric compound.Prompting salvianolic acid A compositions has and suppresses the effect that the rat thrombus in vivo forms, and points out it to can be used for preventing and treating the ischemic heart desease due to thrombosis.
Medical science and study of pharmacy personnel can't, in advance under the prerequisite of not doing related experiment, learn that the salvianolic acid A compositions has above-mentioned good purposes in advance.
The accompanying drawing explanation
Fig. 1. salvianolic acid A hydrogen nuclear magnetic resonance spectrogram;
Fig. 2. salvianolic acid A carbon-13 nmr spectra figure;
Fig. 3. alkannic acid hydrogen nuclear magnetic resonance spectrogram;
Fig. 4. alkannic acid carbon-13 nmr spectra figure;
Fig. 5. rosmarinic acid hydrogen nuclear magnetic resonance spectrogram;
Fig. 6. rosmarinic acid carbon-13 nmr spectra figure;
Fig. 7. salvianolic acid B nuclear magnetic resonance, NMR oxygen spectrogram;
Fig. 8. salvianolic acid B carbon-13 nmr spectra figure;
Fig. 9. salvianolic acid C hydrogen nuclear magnetic resonance spectrogram;
Figure 10. salvianolic acid C carbon-13 nmr spectra figure;
Figure 11. mix reference substance solution HPLC figure;
Figure 12. alkannic acid reference substance solution HPLC figure;
Figure 13. rosmarinic acid reference substance solution HPLC figure;
Figure 14. salvianolic acid B reference substance solution HPLC figure;
Figure 15. salvianolic acid A reference substance solution HPLC figure;
Figure 16. salvianolic acid C reference substance solution HPLC figure;
Figure 17. salvianolic acid A compositions HPLC figure;
The specific embodiment
Embodiment 1
Get red rooted salvia, be ground into 6 order granules, add 92 ℃ of water of 7 times of amounts at every turn, warm macerating extracts 3 times, with 25 rev/mins of speed, stirs simultaneously, and each warm macerating extracts 3 hours, extracting solution is evaporated to relative density 1.20 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 4.0 with 10% sodium hydroxide, adds 0.5%ZnCl 2as catalyst, 120 ℃ of temperature thermal conversions 4 hours, 20% phosphoric acid adjust pH to 2.5 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 3mg, through the HPD-100 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 50 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 10, uses respectively 3 times of cylinder hydrops, 5 times of column volume 25% ethanol elutions, removes impurity, use again 4 times of column volume 40% ethanol elutions, HPLC detects, and collects the 40% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 5mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 10 with the polyamide ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3 times of cylinder hydrops, 12 times of column volume 40% alcoholic solution eluting remove impurity, use 8 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 15mg aqueous solution, aqueous solution is adjusted pH to 2.5 with 20% phosphoric acid, and by the t-butyl methyl ether of 3 times of amounts of aqueous solution, minute 3 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 1～3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 15 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 10, take pentane-t-butyl methyl ether as eluant, gradient elution, use respectively pentane: 10 times of column volumes of t-butyl methyl ether (4: 6) eluting, pentane: 10 times of column volumes of t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 12 times of water gagings and dissolves, with microwave vacuum drying (50 ℃ of baking temperatures, 4 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 60KW) 130 minutes, obtain the salvianolic acid A compositions.
After measured, in described salvianolic acid A compositions, salvianolic acid A content is 94.57%, alkannic acid content 0.663%; Rosmarinic acid contents 1.16%; Content of danshinolic acid B 1.24%; Salvianolic acid C content 1.48%.
Embodiment 2
Get red rooted salvia, be cut into decoction pieces, add 90 ℃ of water temperature lixiviates of 8 times of amounts at every turn and get 3 times, stir with 20 rev/mins of speed simultaneously, each warm macerating extracts 2.5 hours, extracting solution is evaporated to relative density 1.10 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 15mg, aqueous solution is adjusted pH to 5.0 with 10% potassium hydroxide, adds 0.6%FeCl 3as catalyst, 120 ℃ of temperature thermal conversions 3.5 hours, 15% hydrochloric acid adjust pH to 2.5 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-100 macroporous resin column chromatography, separate, salvianolic acid A, applied sample amount is 1: 45 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3.5 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, remove impurity, use again 5 times of column volume 45% ethanol elutions, HPLC detects, the 45% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 5mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 9 with the polyamide ratio, the resin column blade diameter length ratio is 1: 7, use respectively 4 times of cylinder hydrops, 10 times of column volume 40% alcoholic solution eluting remove impurity, use 8 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 12mg aqueous solution, aqueous solution is adjusted pH to 2.6 with 15% hydrochloric acid, and by the t-butyl methyl ether of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.8g, adds 2～3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 13 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take normal heptane-ethyl acetate as eluant, gradient elution, use respectively 8 times of column volumes of normal heptane-ethyl acetate (4: 6) eluting, 8 times of column volumes of normal heptane-ethyl acetate (7: 3) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 8 times of water gagings and dissolves, vacuum drying (baking temperature: 65 ℃, more than vacuum-0.07Mpa, power 15KW) dry 4 hours, obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 95.53%, alkannic acid content 0.62%; Rosmarinic acid contents 1.14%; Content of danshinolic acid B 1.20%; Salvianolic acid C content 1.48%.
Embodiment 3
Get red rooted salvia, be ground into 4 order to 10 order granules, add 85 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 2 times, stir with 30 rev/mins of speed simultaneously, each warm macerating extracts 3.5 hours, extracting solution is evaporated to relative density 1.18 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 18mg, aqueous solution is adjusted pH to 5.2 with 10% sodium carbonate, adds 0.6%AlCl 3as catalyst, 123 ℃ of temperature thermal conversions 4.5 hours, 15% nitric acid adjust pH to 2.8 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 6mg, through the HPD-100B macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 40 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 7, use respectively 4 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, remove impurity, use again 5 times of column volume 40% ethanol elutions, HPLC detects, the 40% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 6mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 8 with the polyamide ratio, the resin column blade diameter length ratio is 1: 8, use respectively 4 times of cylinder hydrops, 9 times of column volume 40% alcoholic solution eluting remove impurity, use 7 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 10mg aqueous solution, aqueous solution is adjusted pH to 2.6 with 15% nitric acid, and with the methyl acetate of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure methyl acetate is made the extract of every 1ml containing salvianolic acid A 0.7g, adds 3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 10 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 7, take petroleum ether, Ethyl formate is eluant, gradient elution, use respectively 8 times of column volumes of petroleum ether-Ethyl formate (4: 6) eluting, 9 times of column volumes of petroleum ether-Ethyl formate (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 8 times of water gagings and dissolves, spray drying (intake air temperature: 170 ℃, 85 ℃ of air outlet temperature, spray velocity: 150ml/mn), obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 95.38%, alkannic acid content 0.65%; Rosmarinic acid contents 1.12%; Content of danshinolic acid B 1.22%; Salvianolic acid C content 1.47%.
Embodiment 4
Get red rooted salvia, be cut into decoction pieces, add 80 ℃ of water temperature lixiviates of 10 times of amounts at every turn and get 3 times, stir with 15 rev/mins of speed simultaneously, each warm macerating extracts 3 hours, extracting solution is evaporated to relative density 1.20 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 5.4 with 10% sodium bicarbonate, adds 0.8%RuCl 3as catalyst, 128 ℃ of temperature thermal conversions 4.0 hours, 20% sulphuric acid adjust pH to 2.6 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-826 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 40 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 7, use respectively 4 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, remove impurity, use again 5 times of column volume 40% ethanol elutions, HPLC detects, the 40% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 6mg salvianolic acid A, by the ODS chromatographic column, separate, the salvianolic acid A applied sample amount is 1: 10 with the ODS ratio, the resin column blade diameter length ratio is 1: 15, use respectively 4 times of cylinder hydrops, 7 times of column volume 35% alcoholic solution eluting remove impurity, use 6 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 12mg aqueous solution, aqueous solution is adjusted pH to 2.8 with 20% sulphuric acid, and with the butyl acetate of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure butyl acetate is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 2.5 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 9 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take pentane, methyl acetate is eluant, gradient elution, use respectively 8 times of column volumes of pentane-methyl acetate (4.5: 5.5) eluting, 8 times of column volumes of pentane-methyl acetate (6.5: 3.5) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 10 times of water gagings and dissolves, microwave vacuum drying (60 ℃ of baking temperatures, 3 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 10KW) 100 minutes, obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 95.22%, alkannic acid content 0.68%; Rosmarinic acid contents 1.15%; Content of danshinolic acid B 1.26%; Salvianolic acid C content 1.46%.
Embodiment 5
Get red rooted salvia, be ground into 4 order to 10 order granules, add 85 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 20 rev/mins of speed simultaneously, each warm macerating extracts 2.5 hours, extracting solution is evaporated to relative density 1.25 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 10mg, aqueous solution is adjusted pH to 5.5 with 20% sodium citrate, adds 0.4%PdCl 3as catalyst, 132 ℃ of temperature thermal conversions 3.5 hours, 20% acetic acid adjust pH to 2.6 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-826 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 35 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3 times of cylinder hydrops, 4.5 column volume 25% ethanol elution doubly, remove impurity, use again 6 times of column volume 40% ethanol elutions, HPLC detects, the 40% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 8mg salvianolic acid A, by the ODS chromatographic column, separate, the salvianolic acid A applied sample amount is 1: 12 with the ODS ratio, the resin column blade diameter length ratio is 1: 18, use respectively 4 times of cylinder hydrops, 8 times of column volume 30% alcoholic solution eluting remove impurity, use 5 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 15mg aqueous solution, aqueous solution is adjusted pH to 2.7 with 20% acetic acid, and by the ethyl acetate of 5 times of amounts, minute 5 extractions, separate organic layer, and the reclaim under reduced pressure ethyl acetate is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 2 times of amount silica gel, stirs, and volatilizes, be added to stirring sample silica gel 10 showing on dry silicagel column of having installed, the silicagel column blade diameter length ratio is 1: 10, take pentane, methyl acetate is eluant, gradient elution, use respectively 8 times of column volumes of pentane-methyl acetate (4.5: 5.5) eluting, 8 times of column volumes of pentane-methyl acetate (6.5: 3.5) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 12 times of water gagings and dissolves, microwave vacuum drying (65 ℃ of baking temperatures, 3 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 15KW) 120 minutes, obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 95.53%, alkannic acid content 0.61%; Rosmarinic acid contents 1.07%; Content of danshinolic acid B 1.14%; Salvianolic acid C content 1.47%.
Embodiment 6
Get red rooted salvia, be ground into 4 order to 10 order granules, add 88 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 22 rev/mins of speed simultaneously, each warm macerating extracts 3.5 hours, extracting solution is evaporated to relative density 1.23 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 13mg, aqueous solution is adjusted pH to 3.6 with 10% sodium hydroxide, adds 0.5%CuCl 2as catalyst, 133 ℃ of temperature thermal conversions 4.5 hours, 10% hydrochloric acid adjust pH to 2.7 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-D101 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 40 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 9, use respectively 4 times of cylinder hydrops, 4 times of column volume 22% ethanol elutions, remove impurity, use again 6 times of column volume 43% ethanol elutions, HPLC detects, the 43% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every ml containing the 10mg salvianolic acid A, by the ODS chromatographic column, separate, the salvianolic acid A applied sample amount is 1: 15 with the sephadex lh-20 ratio, the resin column blade diameter length ratio is 1: 20, use respectively 4 times of cylinder hydrops, 8 times of column volume 30% alcoholic solution eluting remove impurity, use 5 times of column volumes, 60% alcoholic solution eluting again, collect the 60% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 12mg aqueous solution, aqueous solution is adjusted pH to 2.8 with 10% hydrochloric acid, and with the methyl acetate of 5 times of amounts, minute 5 extractions, separate organic layer, and the reclaim under reduced pressure methyl acetate is made the extract of every 1ml containing salvianolic acid A 0.5g, adds 3 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 12 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 10, take pentane, methyl acetate is eluant, gradient elution, use respectively 6 times of column volumes of pentane-methyl acetate (4: 6) eluting, 7 times of column volumes of pentane-methyl acetate (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 10 times of water gagings and dissolves, microwave vacuum drying (60 ℃ of baking temperatures, 2 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 20KW) 100 minutes, obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 95.44%, alkannic acid content 0.66%; Rosmarinic acid contents 1.11%; Content of danshinolic acid B 1.26%; Salvianolic acid C content 1.46%.
Embodiment 7
Get red rooted salvia, be cut into decoction pieces, add 90 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 25 rev/mins of speed simultaneously, each warm macerating extracts 3 hours; Extracting solution is evaporated to relative density 1.22 (60 ℃), adds ethanol to make to measure 75% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor; Be diluted with water to every 1ml containing salvianolic acid B 20mg, aqueous solution is adjusted pH to 4.0 with 10% sodium carbonate, adds 1.0%ZnCl 2as catalyst, 135 ℃ of temperature thermal conversions 4.5 hours, 15% sulphuric acid adjust pH to 3.0 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the AB-8 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 36 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 9, uses respectively 3 times of cylinder hydrops, 4 times of column volume 25% ethanol elutions, removes impurity, use again 5 times of column volume 45% ethanol elutions, HPLC detects, and collects the 45% ethanol elution part that contains salvianolic acid A, and decompression recycling ethanol also is concentrated into without the alcohol flavor; Aqueous solution is concentrated into the solution of every 1ml containing the 6mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 10 with the polyamide ratio, the resin column blade diameter length ratio is 1: 10, use respectively 4 times of cylinder hydrops, 8 times of column volume 45% alcoholic solution eluting remove impurity, use 8 times of column volumes, 65% alcoholic solution eluting again, collect the 65% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 10mg aqueous solution; Aqueous solution is adjusted pH to 2.7 with 15% sulphuric acid, and by the t-butyl methyl ether of 4 times of amounts, minute 4 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.6g, adds 3 times of amount silica gel, stirs, and volatilizes; Stirring sample silica gel, be added on 10 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take pentane, ethyl acetate is eluant, gradient elution, use respectively 8 times of column volumes of pentane-ethyl acetate (4: 6) eluting, 8 times of column volumes of pentane-ethyl acetate (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 8 times of water gagings and dissolves, microwave vacuum drying (80 ℃ of baking temperatures, 1 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 30KW) 80 minutes, obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 96.12%, alkannic acid content 0.54%; Rosmarinic acid contents 0.92%; Content of danshinolic acid B 1.08%; Salvianolic acid C content 1.34%.
Embodiment 8
Get red rooted salvia, be ground into 4 order to 10 order granules, add 85 ℃ of water temperature lixiviates of 9 times of amounts at every turn and get 3 times, stir with 22 rev/mins of speed simultaneously, each warm macerating extracts 3 hours, extracting solution is evaporated to relative density 1.17 (60 ℃), adds ethanol to make to measure 70% containing alcohol, standing, filters, and decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, be diluted with water to every 1ml containing salvianolic acid B 25mg, aqueous solution is adjusted pH to 4.2 with 10% sodium citrate, adds 0.8%ZnCl 2as catalyst, 133 ℃ of temperature thermal conversions 4.5 hours, 10% hydrochloric acid adjust pH to 2.8 for conversional solution, centrifugal, supernatant is evaporated to every 1ml containing salvianolic acid A 5mg, through the HPD-300 macroporous resin column chromatography, separate, the salvianolic acid A applied sample amount is 1: 45 with the macroporous adsorbent resin ratio, the resin column blade diameter length ratio is 1: 10, use respectively 5 times of cylinder hydrops, 6 times of column volume 20% ethanol elutions, remove impurity, use again 5 times of column volume 45% ethanol elutions, HPLC detects, the 45% ethanol elution part that collection contains salvianolic acid A, decompression recycling ethanol also is concentrated into without the alcohol flavor, aqueous solution is concentrated into the solution of every 1ml containing the 8mg salvianolic acid A, by polyamide chromatography post, separate, the salvianolic acid A applied sample amount is 1: 12 with the polyamide ratio, the resin column blade diameter length ratio is 1: 8, use respectively 3 times of cylinder hydrops, 6 times of column volume 45% alcoholic solution eluting remove impurity, use 8 times of column volumes, 55% alcoholic solution eluting again, collect the 55% alcoholic solution part that contains salvianolic acid A, decompression recycling ethanol also is concentrated into every 1ml containing salvianolic acid A 10mg aqueous solution, aqueous solution is adjusted pH to 2.9 with 15% hydrochloric acid, and by the t-butyl methyl ether of 5 times of amounts, minute 5 extractions, separate organic layer, and the reclaim under reduced pressure t-butyl methyl ether is made the extract of every 1ml containing salvianolic acid A 0.6g, adds 2.5 times of amount silica gel, stirs, and volatilizes, stirring sample silica gel, be added on 12 times of dry silicagel columns of amount that installed, the silicagel column blade diameter length ratio is 1: 8, take pentane, t-butyl methyl ether is eluant, gradient elution, use respectively 8 times of column volumes of pentane-t-butyl methyl ether (4: 6) eluting, 8 times of column volumes of pentane-t-butyl methyl ether (6: 4) eluting, the reclaim under reduced pressure eluant, salvianolic acid A after the recovery organic solvent adds 9 times of water gagings and dissolves, microwave vacuum drying (60 ℃ of baking temperatures, 3 ℃ of return difference temperature, more than vacuum-0.07Mpa, microwave power 15KW) 100 minutes, obtain the salvianolic acid A compositions.
After measured, in the salvianolic acid A compositions, salvianolic acid A content is 95.34%, alkannic acid content 0.63%; Rosmarinic acid contents 1.08%; Content of danshinolic acid B 1.19%; Salvianolic acid C content 1.47%.
Experimental example 1: salvianolic acid A compositions analytical method and separation, Structural Identification research
One, salvianolic acid A compositions analytical method research
1. instrument and reagent
Instrument: Waters e2695 high performance liquid chromatograph, Empower 2 chromatographic work stations, 2998 diode array detector; Sartorius cp225D 100,000/electronic balance.
Chromatographic column: YMC C 18chromatographic column (250 * 4.6mm, 5 μ m);
Reagent: methanol is chromatographically pure, and water is ultra-pure water prepared by Millipore, and other reagent are analytical pure.
Rosmarinic acid reference substance, salvianolic acid B reference substance are all purchased from Nat'l Pharmaceutical & Biological Products Control Institute, for assay; Alkannic acid reference substance, salvianolic acid C reference substance are all purchased from the bright bio tech ltd in sea, Shanghai, and the salvianolic acid A reference substance, for self-control, is 99.52% through purity mark content.
2. the preparation of reference substance solution and need testing solution
2.1 the preparation of reference substance solution: precision takes the about 10.00mg of alkannic acid reference substance respectively, the about 10.00mg of rosmarinic acid reference substance, the about 10.00mg of salvianolic acid B reference substance, the about 10.00mg of salvianolic acid C reference substance, the about 10.00mg of salvianolic acid A reference substance, put in different 100ml measuring bottles, add respectively dissolve with methanol and be diluted to scale, shake up, precision is drawn the alkannic acid reference substance respectively, the rosmarinic acid reference substance, the salvianolic acid B reference substance, each 10ml of salvianolic acid C reference substance, put in different 100ml measuring bottles, add respectively dissolve with methanol and be diluted to scale, shake up, product stock solution in contrast.Accurate each 10ml of above-mentioned stock solution that draws, put in same 100ml measuring bottle, adds methanol and be diluted to scale, shakes up, as mixing reference substance solution.
2.3 the preparation precision of need testing solution takes the about 10.00mg of embodiment 1 sample, puts in the 50ml measuring bottle, adds dissolve with methanol and is diluted to scale, the accurate absorption in 10ml to 100ml measuring bottle, add methanol and be diluted to scale, shakes up, and obtains.
3. chromatographic condition and system suitability
Take octadecylsilane chemically bonded silica as filler; Flow velocity 1.0ml/min; Detect wavelength: 286nm; 30 ℃ of column temperatures; Number of theoretical plate calculates and should be not less than 10000 by the salvianolic acid A peak.
In the time of 0～10 minute, the ratio of methanol is down to 60% by 30% ratio that rises to 40%, 0.1～0.5% phosphate aqueous solution by 70%; In the time of 10～30 minutes, the ratio of methanol is down to 45% by 40% ratio that rises to 55%, 0.1～0.5% phosphate aqueous solution by 50%; In the time of 30～60 minutes, the ratio of methanol is down to 20% by 55% ratio that rises to 80%, 0.1～0.5% phosphate aqueous solution by 45%.
Under these conditions, the chromatographic peak retention time of 5 reference substances is shown in Figure 11～17 in Table 1, HPLC collection of illustrative plates.
The chromatographic peak retention time result of each reference substance of table 1.
Figure BSA00000811649200261
4. the investigation of linear relationship
Accurate above-mentioned mixing reference substance solution 0.1ml, 0.2ml, 0.5ml, 1ml, 2ml, the 5ml of drawing, put respectively in the 10ml measuring bottle, adds methanol and be diluted to series standard solution.Accurate each the 10 μ l injection liquid chromatographies of above-mentioned standard solution of drawing, calculate peak area by " 3. chromatographic condition and system suitability " lower chromatographic condition, take the peak area integrated value respectively as vertical coordinate, and each concentration reference substance sample size is abscissa, the drawing standard curve.Result shows to mix reference substance solution and become good linear relationship in following scope, in Table 2.
Table 2. mixes reference substance solution linear relationship result
Figure BSA00000811649200262
5. precision test
Get the mixing reference substance solution, measure according to " 3. chromatographic condition and system suitability " lower chromatographic condition, repeat sample introduction 6 times.Result shows that the precision of the method is good, in Table 3.
Table 3 Precision test result
Figure BSA00000811649200271
6. stability test
Get need testing solution, according to " 3. chromatographic condition and system suitability " lower chromatographic condition, measure, at regular intervals sample introduction once, as a result in need testing solution each composition in 24 hours peak area without significant change, show having good stability of need testing solution, in Table 4.
Table 4 stability test result
7. replica test
Get this salvianolic acid A compositions, add methanol and make 6 parts of need testing solutions, measure according to " 3. chromatographic condition and system suitability " lower chromatographic condition.Result shows that the method repeatability is good, in Table 5.
Table 5. replica test result
Figure BSA00000811649200273
8. recovery test
Adopt the application of sample recovery test, get the salvianolic acid A compositions 10mg of known content, accurately weighed, parallel 6 parts, add corresponding reference substance solution by each constituent content equal proportion respectively, by 2.3 below legal system available test sample solutions, measure and calculate average recovery and the RSD of each composition.Result shows that the accuracy of the method is good, in Table 6.
Table 6. recovery test result
Two, salvianolic acid A compositions separation, Structural Identification research
Embodiment 1 is obtained to above-mentioned salvianolic acid A compositions respectively with CG161M macroporous adsorbent resin, ODS, Sephadex LH-20 column chromatography for separation, with water: ethanol gradient elution, the ratio of water is 80～20%, and the ratio of ethanol is 20～80%, the Fractional Collections eluent, merge same composition, crystallization, can obtain salvianolic acid A, the monomeric compound of alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C, measure described monomeric compound, wherein:
Salvianolic acid A, molecular formula: C 26h 222o 10, molecular weight: 494.45, structure is as follows:
Figure BSA00000811649200291
Salvianolic acid A physicochemical property and spectral data, referring to Fig. 1,2.
Salvianolic acid A (Salvianolic acid A), pale yellow powder, easily easy methanol, water.ESIMS m/z:493[M-H] -, 518[M+Na] +, molecular formula: C 26h 22o 10, molecular weight: 494.45; 1h (600MHz, CD 3oD) and 13c NMR (150MHz, CD 3oD) data are as follows:
1NMR(CD 3OD，600MHz)δ：2.96(1H，dd，J＝14.4，8.4Hz，H-7``)，3.06(1H，dd，J＝14.4，4.2Hz，H-7``)，5.17(1H，dd，J＝9.0，4.2Hz，H-8``)，6.27(1H，d，J＝16.2Hz，H-8`)，6.54(1H，dd，J＝7.8，1.8Hz，H-6``)，6.63(1H，d，J＝7.8Hz，H-5``)，6.65(1H，d，J＝16.2，Hz，H-7)，6.72(1H，d，J＝8.4Hz，H-4`)，6.74(1H，d，J＝8.4Hz，H-5)，6.76(1H，d，J＝1.8Hz，H-2``)，6.88(1H，dd，J＝8.4，1.8Hz，H-6)，7.05(1H，d，J＝1.8Hz，H-2)，7.11(1H，d，J＝8.4Hz，H-5`)，7.14(1H，d，J＝16.2Hz，H-8)；8.06(1H，d，J＝16.2Hz，H-7`).
13CNMR(CD 3OD，150MHz)δ：36.6(C-7``)，73.3(C-8``)，112.6(C-2)，113.4(C-5)，114.2(C8`)，114.9(C-4`)，115.1(C-5``)，116.0(C-2``)，118.7(C-5`)，119.6(C-6)，119.3(C-8)，120.6(C-6``)，124.7(C-6`)，127.0(C-1)，127.9(C-1``)，130.0(C-1`)，136.5(C-7)，143.1(C-3)，143.9(C-3``)，144.8(C-4``)，145.1(C-2`)，145.4(C-4)，146.0(C-7`)，146.9(C-3`)，167.3(C-9`)，172.1(C-9``).
Alkannic acid, its molecular formula: C 27h 22o 12, molecular weight: 538.46, structure is as follows:
Figure BSA00000811649200301
Alkannic acid physicochemical property and spectral data, referring to Fig. 3,4.
Alkannic acid (lithospcrmic acid), pale yellow powder, easily easy methanol, water.ESIMSm/z:539[M+H] +, 537[M-1] -, 560[M+Na] -, 492[M-COOH] -; Molecular formula: C 27h 22o 12, molecular weight 538.45; 1h (600MHz, CD 3oD) and 13c NMR (150MHz, CD 3oD) data are as follows:
1NMR(CD 3OD，600MHz)δ：3.02(1H，dd，J＝14.4，9.6Hz，H-7``)，3.06(1H，dd，J＝14.4，3.0Hz，H-7``)，4.25(1H，dd，J＝5.4Hz，H-8`)，4.97(1H，dd，J＝9.6，3.0Hz，H-8``)，5.88(1H，d，J＝5.4Hz，H-7`)，6.31(1H，d，J＝16.0Hz，H-8)，6.59(1H，dd，J＝8.0，1.8Hz，H-6``)，6.65(1H，d，J＝8.0Hz，H-5``)，6.73(1H，dd，J＝8.4，2.0Hz，H-6`)，6.74(1H，d，J＝1.8Hz，H-2``)，6.74(1H，d，J＝8.4Hz，H-5`)，6.83(1H，d，J＝8.4Hz，2.4Hz，H-5)，6.97(1H，d，J＝2.0Hz，Hz，H-2`)，7.13(1H，d，J＝8.4Hz，H-6)；7.93(1H，d，J＝16.0Hz，H-7).
13CNMR(CD 3OD，150MHz)δ：37.3(C-7``)，59.9(C-8`)，76.7(C-8``)，88.9(C-7`)，112.4(C-2``)，114.6(C-5``)，114.9(C-5`)，115.7(C-8)，116.1(C-2`)，117.2(C-6``)，119.5(C-6)，119.9(C-6`)，123.5(C-1)，129.3(C-2)，129.8(C-1``)，133.4(C-1`)，142.4(C-7)，143.3(C-4)，143.4(C-3``)，144.7(C-4``)，145.1(C-3`)，145.1(C-4`)，147.4(C-3)，167.8(C-9)，176.5(C-9``)，178.5(C-9`).
The molecular formula of rosmarinic acid: C 18h 16o 8, molecular weight: 360.31, structure is as follows:
Figure BSA00000811649200302
Rosmarinic acid physicochemical property and spectral data, referring to Fig. 5,6.
Rosmarinic acid (Rosmarinic acid), white powder, easily easy methanol, water.ESIMS m/z:359[M-H] -, 383[M+Na] +; Molecular formula: C 18h 16o 8, molecular weight 360.31; 1h (600MHz, CD 3oD) and 13c NMR (150MHz, CD 3oD) data are as follows:
1NMR(CD 3OD，600MHz)δ：3.01(1H，dd，J＝14.4，8.4Hz，H-7`)，3.10(1H，dd，J＝14.4，4.2Hz，H-7`)，5.18(1H，dd，J＝8.4，4.2Hz，H-8`)，6.27(1H，d，J＝16.0Hz，H-8)，6.61(1H，dd，J＝7.8，1.8Hz，H-6`)，6.70(1H，d，J＝7.8Hz，H-5`)，6.75(1H，d，J＝1.8Hz，H-2`)，6.78(1H，d，J＝8.4Hz，H-5)，6.95(1H，dd，J＝8.4，2.4Hz，H-6)，7.04(1H，d，J＝1.8Hz，H-2)，7.55(1H，d，J＝16.0Hz，H-7)；
13CNMR(CD 3OD，150MHz)δ：36.6(C-7`)，73.2(C-8`)，113.1(C-8)，113.9(C-2)，114.9(C-5)，115.1(C-5`)，116.2(C-2`)，120.4(C-6)，121.8(C-6`)，126.3(C-1)，127.9(C-1`)，143.9(C-3)，144.8(C-4)，145.5(C-3`)，146.4(C-4`)，148.4(C-7)，167.1(C-9)，172.1(C-9`).
Salvianolic acid B, its molecular formula: C 36h 30o 16, molecular weight: 718.61, structure is as follows:
Figure BSA00000811649200311
Salvianolic acid B physicochemical property and spectral data, referring to Fig. 7,8.
Salvianolic acid B (Salvianolic acid B), pale yellow powder, easily easy methanol, water.ESIMSm/z:717[M-H] -, 741[M+Na] +; Molecular formula: C 36h 30o 16, molecular weight 718.62; 1h (600MHz, CD 3oD) and 13c NMR (150MHz, CD 3oD) data are as follows:
1NMR(CD 3OD，600MHz)δ：2.80-3.10(2H，m，H-7``)，2.80-3.10(2H，m，H-7```)，4.35(1H，d，J＝4.8Hz，H-8``)，5.15-5.19(1H，m，H-8`)，5.15-5.19(1H，m，H-8```)，5.85(1H，d，J＝4.8Hz，H-7``)，6.20(1H，d，J＝16.2Hz，H-8)，6.31(1H，dd，J＝8.1，2.1Hz，H-6`)，6.52(1H，d，J＝2.4Hz，H-2```)，6.54(1H，d，J＝7.8Hz，H-5``)，6.62(1H，d，J＝2.1Hz，H-2`)，6.66(1H，dd，J＝8.1，2.4Hz，H-6```)，6.70(1H，d，J＝7.8Hz，H-5`)，6.74(1H，d，J＝8.1Hz，H-5```)，6.75(1H，dd，J＝7.8，2.4Hz，H-6``)，6.76(1H，d，J＝2.4Hz，H-2``)，6.83(1H，d，J＝8.4Hz，H-5)，7.16(1H，d，J＝8.4Hz，H-6)，7.52(1H，d，J＝16.2Hz，H-7)；
13CNMR(CD 3OD，150MHz)δ：36.111(C-7```)，36.51(C-7`)，56.58(C-8``)，73.28(C-8)，74.19(C-8```)，86.93(C-7``)，111.99(C-2``)，115.01(C-5``)，115.04(C-5`)，115.13(C-2`)，115.18(C-2```)，115.95(C-8)，116.20(C-6``)，116.97(C-5```)，117.04(C-5)，120.37(C-6)，120.89(C-6```)，123.28(C-1)，125.04(C-2)，127.55(C-1`)，127.85(C-1```)，132.27(C-1``)，142.20(C-7)，143.70(C-3```)，143.72(C-4```)，143.88(C-4``)，144.57(C-3``)，144.73(C-4`)，145.23(C-3`)，145.39(C-3)，147.71(C-4)，166.66(C-9)，170.92(C-9```)，171.17(C-9``)，172.29(C-9`).
Salvianolic acid C, its molecular formula: C 26h 20o 10, molecular weight: 492.43, structure is as follows:
Figure BSA00000811649200321
Salvianolic acid C physicochemical property and spectral data, referring to Fig. 9,10.
Salvianolic acid C (Salvianolic acid C), pale yellow powder, easily easy methanol, water.ESIMSm/z:491[M-H] -, 515[M+Na] +; Molecular formula: C 26h 20o 10, molecular weight 492.43; 1h (600MHz, CD 3oD) and 13c NMR (150MHz, CD 3oD) data are as follows:
1NMR(CD 3OD，600MHz)δ：3.07(1H，dd，J＝13.8，8.4Hz，H-7``)，3.15(1H，dd，J＝13.8，4.2Hz，H-7``)，5.25(1H，dd，J＝8.4，4.2Hz，H-8``)，6.46(1H，d，J＝15.9Hz，H-8)，6.46(1H，dd，J＝8.1，2.1Hz，H-2``)，6.72(1H，d，J＝8.1Hz，H-3``)，3.74(1H，d，J＝8.4Hz，H-5)，6.80(1H，d，J＝2.4Hz，H-6``)，6.88(1H，d，J＝7.8Hz，H-5`)，7.20(1H，s，，H-8`)，7.36(1H，d，J＝7.8Hz，H-6)，7.37(1H，dd，J＝7.8Hz，2.4H z，H-6`)，7.40(1H，d，J＝2.4Hz，2.1Hz，H-2`)，7.94(1H，d，J＝15.9Hz，H-7)；
13CNMR(CD 3OD，150MHz)δ：36.2(C-7``)，73.3(C-8``)，97.9(C-8`)，110.4(C-5)，112.0(C-2`)，113.5(C-8)，114.9(C-5``)，115.4(C-5`)，116.3(C-2``)，117.4(C-6`)，118.2(C-1)，120.5(C-6``)，122.0(C-1`)，125.0(C-6)，128.0(C-1``)，131.3(C-2)，143.0(C-3)，143.8(C-7)，144.0(C-3``)，144.6(C-4)，144.8(C-4``)，145.3(C-2`)，146.7(C-4`)，158.0(C-7`)，167.3(C-9)，172.4(C-9``).
Experimental example 2: the extraction of salvianolic acid B
1.1 extract the confirmation of solvent and extracting method
Take red rooted salvia 400g, the method under Chinese Pharmacopoeia Radix Salviae Miltiorrhizae item of pressing is measured content of danshinolic acid B, is divided into 4 parts, by following testing program, is tested:
Experiment 1: get red rooted salvia 100g, add 8 times of water gagings at every turn and extract 1.5 hours at 80 ℃ of warm macerating, warm macerating extracts three times altogether, and merge extractive liquid, is measured salvianolic acid B and calculates extraction ratio, and result is as table 7.
Experiment 2: get red rooted salvia 100g, add 8 times of water gagings at every turn and extract 1.5 hours at 80 ℃ of warm macerating, stir with 10～50 rev/mins of speed simultaneously, warm macerating stirs and extracts three times altogether, and merge extractive liquid, is measured salvianolic acid B and calculates extraction ratio, and result is as table 7.
Experiment 3: get red rooted salvia 100g, add 8 times of water gagings at every turn and decoct 1.5 hours, decoct altogether three times, merge extractive liquid,, measure salvianolic acid B and calculate extraction ratio, and result is as table 7.
Experiment 4: get red rooted salvia 100g, add 8 times of amount 50% alcohol reflux 1.5 hours at every turn, extract altogether three times, merge extractive liquid,, measure salvianolic acid B and calculate extraction ratio, and result is as table 7.
Table 7. extracts solvent and extracting method experimental result
Figure BSA00000811649200331
Above-mentioned experimental result shows, adopt 50% ethanol to make the extraction solvent influential to the salvianolic acid B extraction ratio, 50% ethanol extraction is better than water extraction, but soak and add that stir to extract difference little with water temperature, two kinds of extracting modes that stir in the water extraction process and do not stir are influential to the extraction ratio of salvianolic acid B, decocting extraction may be because temperature is higher, to salvianolic acid B, extracts influential.
1.2 the preferred extraction process of orthogonal experiment
1.2.1 the optimization of water extraction process research: according to above result of the test, water extraction process is usingd extraction time (A), extraction time (B), quantity of solvent (C), extract four of temperature (D) as the investigation factor, each factor is established three levels, presses L9 (3 4) orthogonal table carries out Orthogonal Experiment and Design (table 8, table 9), the extraction ratio that to investigate index be salvianolic acid B.
Table 8. extraction factor water-glass
Figure BSA00000811649200341
Table 9. extraction process orthogonal experiments table
Figure BSA00000811649200342
Table 10. the results of analysis of variance table
Figure BSA00000811649200343
Figure BSA00000811649200351
F 0.05(2，2)＝19.00 F 0.01(2，2)＝99.00
The water extraction the results of analysis of variance shows, each experimental factor is to the extraction rate of transform of salvianolic acid B there are no significant difference, therefore the water extraction condition of salvianolic acid B of the present invention is for adding 3～15 times of water gagings, extracting 1～3 time at 45～95 ℃ of lower warm macerating, with 10～50 rev/mins of speed, stir simultaneously, extract 1～4 hour at every turn or add 3～15 times of amounts at every turn and decoct extraction, the each extraction 1～4 hour, extract 1～3 time altogether.
1.2.2 the optimization of alcohol extraction technique research: according to above result of the test, alcohol extraction technique is usingd extraction time (A), four of extraction times (B), quantity of solvent (C), concentration of alcohol (D) be as the investigation factor, each factor is established three levels, presses L9 (3 4) orthogonal table carries out Orthogonal Experiment and Design (table 11, table 12), the extraction ratio that to investigate index be salvianolic acid B.
Table 11. extraction factor water-glass
Figure BSA00000811649200352
Table 12. extraction process orthogonal experiments table
Figure BSA00000811649200353
Figure BSA00000811649200361
Table 13. the results of analysis of variance table
Figure BSA00000811649200362
F 0.05(2，2)＝19.00 F 0.01(2，2)＝99.00
Alcohol reflux extracts the results of analysis of variance and shows, each experimental factor, to the extraction rate of transform of salvianolic acid B there are no significant difference, therefore the extraction conditions of this salvianolic acid B is measured 30%～60% alcohol reflux 1～3 time for adding 3～15 times, extracts 1～4 hour at every turn.
1.3 salvianolic acid B raw material preparation
According to above-mentioned orthogonal experiment Optimization Technology, get red rooted salvia 10kg, add 8 times of water gagings at every turn and extract 1.5 hours at 80 ℃ of warm macerating, with 10～50 rev/mins of speed, stir simultaneously, warm macerating stirs and extracts 3 times altogether, filters merging filtrate, extracting solution is evaporated to relative density 1.10～1.25 (60 ℃), add ethanol to make to measure 60% containing alcohol, filter, decompression filtrate recycling ethanol also is concentrated into without the alcohol flavor, vacuum drying, salvianolic acid extract 4.15kg, recording content of danshinolic acid B is 10.25%.
Experimental example 3: salvianolic acid B transforms the salvianolic acid A composition process relatively
Experiment 1: get the about 30g of salvianolic acid B raw material of preparation under 1.3, be mixed with 200ml solution, add 10% sodium hydroxide solution adjust pH to 4.5;
Experiment 2: get the about 30g of salvianolic acid B raw material of preparation under 1.3, be mixed with 200ml solution, add 10% sodium hydroxide solution adjust pH to 4.5, add 1.0%ZnCl 2;
Experiment 3: get containing the about 6g of salvianolic acid B (content 51.54%) raw material, adding purified water, to be diluted to salvianolic acid B concentration be 15mg/ml solution, adds carbamide, and making it with the mol ratio of salvianolic acid B is 0.5;
Above-mentioned each experimental group is placed in same autoclave, and under 120 ℃, reaction is 4.0 hours, cooling, calculates salvianolic acid A compositions productive rate.
Table 14. salvianolic acid B transforms salvianolic acid A compositions experimental result
The demonstration of table 14 result, the salvianolic acid B high-purity, on transforming not impact, does not need to be purified to more than 50% to be transformed, and salvianolic acid B is converted in salvianolic acid A compositions process, regulates pH value, adds 1.0%ZnCl 2, can greatly improve the productive rate of salvianolic acid A compositions.
Experimental example 4: salvianolic acid B transforms the optimization of salvianolic acid A composition process
Above-mentioned experimentation proves, salvianolic acid B purity is not to affect the factor that salvianolic acid B transforms the salvianolic acid A compositions, but adds certain catalysts influence salvianolic acid B to transform the salvianolic acid A compositions, and therefore, we all add 1%ZnCl to each experimental group 2as catalyst, be converted into other factors of salvianolic acid A compositions to affecting salvianolic acid B: salvianolic acid B concentration (A), pH (B), temperature (C), time (D) are carried out orthogonal test, and each factor is established three levels, presses L9 (3 4) descend the friendship table to carry out EXPERIMENTAL DESIGN (table 15, table 16), the productive rate that the investigation index is the salvianolic acid A compositions.
Table 15. transforming agent water-glass
Figure BSA00000811649200372
Table 16. conversion process orthogonal experiments table
Figure BSA00000811649200381
Table 17. the results of analysis of variance table
Figure BSA00000811649200382
*F 0.05(2，2)＝19.00 △F 0.01(2，2)＝99.00
The results of analysis of variance demonstration, the optimum condition that this orthogonal test is optimized according to intuitive analysis is A 3b 2c 2d 2factor A (salvianolic acid B concentration) has certain influence to salvianolic acid A compositions productive rate, from the K value, analyze, concentration is converted into salvianolic acid A to improving salvianolic acid B effect higher than 30mg/ml has no significant effect, and the impurity formed is more, therefore, transform front salvianolic acid B concentration and should select 1～30mg/ml; Factor B (pH), factor C (temperature) have utmost point significant difference to salvianolic acid A compositions productive rate, in prompting salvianolic acid B conversion process, should strictly control pH and temperature, can success realize transforming to the salvianolic acid A compositions of salvianolic acid B higher yields.
Experimental example 5: catalyst Z nCl 2the impact of consumption on transforming
Transform salvianolic acid A composition process optimal conditions by above-mentioned salvianolic acid B, get the salvianolic acid B raw material, add purified water 200ml, make the solution that salvianolic acid B concentration is 15mg/ml, regulating pH is 4.5, and conversion temperature is 120 ℃, and transformation time is 4 hours, by with the salvianolic acid B molar percentage, add respectively not commensurability catalyst Z nCl 2, the results are shown in Table 18.
Table 18. catalyst Z nCl 2consumption affects experimental result to transforming
Figure BSA00000811649200391
Catalyst Z nCl 2consumption affects experimental result to conversion and shows, catalyst amount>=0.02% can produce 55.65% conversion ratio, preferred catalyst consumption 0.1%～3.0%, and more preferably, after 0.5%～2.0%. catalyst amount>3%, conversion ratio no longer is significantly improved.
Experimental example 6: catalyst transforms the catalytic action of salvianolic acid A compositions to salvianolic acid B
Transform salvianolic acid A composition process optimal conditions by above-mentioned salvianolic acid B, get the salvianolic acid B raw material, add purified water 200ml, make the solution that salvianolic acid B concentration is 15mg/ml, regulating pH is 4.5, and conversion temperature is 120 ℃, and transformation time is 4 hours, add respectively the catalyst of different cultivars and various dose to be transformed, the results are shown in Table 19.
Table 19. different catalysts transforms the impact of red A compositions on red B
Table 19 result shows, above 4 kinds of catalyst all can be used as the catalyst in the salvianolic acid B conversion reaction, and each catalyst amount and salvianolic acid B molar percentage be 0.5%～3.0%, the productive rate of salvianolic acid A compositions >=40%.Conversion ratio surpasses 60%.
Experimental example 7: the purification with macroreticular resin of salvianolic acid A compositions
Get the salvianolic acid A compositions and transform 13 parts of solution, put in each model macroporous resin 100g that pretreatment is good, after shaking table dynamic adsorption 8 hours, the dress post, wash successively 3 column volumes of eluting, 5 column volumes of 20% ethanol elution, 5 column volumes of 70% ethanol elution with water, collect 70% ethanol containing salvianolic acid A compositions eluent part, carry out the salvianolic acid A assay, the eluent evaporate to dryness calculates dry cream amount, the results are shown in Table 20.
The confirmation of table 20. macroporous resin model
Figure BSA00000811649200402
Figure BSA00000811649200411
Result shows: above 13 kinds of macroporous resins are good to the adsorption effect of salvianolic acid A compositions, and can well remove impurity with the ethanol gradient elution of variable concentrations, obtain the salvianolic acid A compositions eluent that content is greater than 75%.
Experimental example 8: the column chromatography purification for the second time of salvianolic acid A compositions
Get 3 parts of salvianolic acid A composition solutions after purification with macroreticular resin, put in each model resin 100g that pretreatment is good, after shaking table dynamic adsorption 8 hours, the dress post, wash successively 3 column volumes of eluting, 5 column volumes of 20% ethanol elution, 5 column volumes of 70% ethanol elution with water, collect 70% ethanol elution and carry out the salvianolic acid A assay, part eluent evaporate to dryness calculates dry cream amount, the results are shown in Table 21.
The confirmation of table 21. resin model
Result shows: above 3 kinds of resins are good to the adsorption effect of salvianolic acid A, and can well remove impurity with the ethanol gradient elution of variable concentrations, obtain content and are about 90% salvianolic acid A compositions eluent.
Experimental example 9: the abstraction purification of salvianolic acid A compositions
By 70% ethanol elution decompression recycling ethanol after post layer column purification for the second time, adjust pH 2.0～4.0, use again n-butyl alcohol, t-butyl methyl ether, methyl acetate, ethyl acetate, butyl acetate, Ethyl formate, ethanol extraction 5 times, the Separation of Organic phase, reclaim solvent, drying, obtain the salvianolic acid A compositions, measure salvianolic acid A content, the results are shown in Table 22.
The confirmation of organic solvent for table 22. extraction
Figure BSA00000811649200421
Table 22 result shows: n-butyl alcohol is because polarity is large, the salvianolic acid A amount of composition is maximum, but its salvianolic acid content is not improved significantly, ether is because polarity is less than normal, water-solubility impurity is few, and salvianolic acid A content is high, but the salvianolic acid A amount of composition obtained is few, the salvianolic acid A amount of composition that other extraction solvent t-butyl methyl ether, methyl acetate, ethyl acetate, butyl acetate, Ethyl formate obtain is larger, and salvianolic acid A content all is improved.
Experimental example 10: the purification by silica gel column chromatography of salvianolic acid A compositions
Get 12 parts of salvianolic acid A compositions extracts after abstraction purification, every part containing salvianolic acid A 10g, adds the silica gel of 20g, stirs, and volatilizes; Stirring sample silica gel, be added on the dry silicagel column of the 100g installed, the two-phase solvent that petroleum ether, pentane, normal heptane, ethyl acetate, methyl acetate, Ethyl formate, t-butyl methyl ether form of take respectively is eluant, HPLC or thin layer chromatography detect, collect salvianolic acid A compositions eluent, the eluent evaporate to dryness, get dry extract, measure salvianolic acid A content, the results are shown in Table 23.
The confirmation of table 23. eluant
Figure BSA00000811649200422
Figure BSA00000811649200431
Result shows: when the salvianolic acid A compositions is used normal phase silica gel column chromatography, the two-phase solvent that adopts petroleum ether, lower pentane, normal heptane, ethyl acetate, methyl acetate, Ethyl formate, t-butyl methyl ether to form is eluant, gradient elution, can well remove impurity, obtain highly purified salvianolic acid A compositions eluent.
Experimental example 11: salvianolic acid A composition dries method research
Get 4 parts of salvianolic acid A compositions eluents after purification by silica gel column chromatography, every part containing salvianolic acid A 100g, be concentrated into without the thick paste shape, adding after 10 times of water gagings dissolve adopts respectively vacuum drying, lyophilisation, spray drying, microwave vacuum drying to obtain the salvianolic acid A compositions, said composition is detected, be the results are shown in Table 24.
Table 24. salvianolic acid A composition dries method testing result
Result shows: adopt the lyophilisation overlong time, and high cost, and organic solvent residual is serious; And that vacuum drying, spray drying, microwave vacuum drying process are controlled is simple, treating capacity is large, and baking temperature is low, and the time is short, and gained salvianolic acid A compositions indices is good, therefore the present invention adopts vacuum drying, spray drying or microwave vacuum drying.
Through further experiment is definite, the microwave vacuum drying optimum range is chosen as temperature: 20-100 ℃, and return difference temperature 1-5 ℃, more than vacuum-0.07Mpa, microwave power 1-100KW, dry 10-200 minute;
The vacuum drying optimum range is chosen as temperature: 50 ℃～90 ℃, and more than vacuum-0.07Mpa, power: 1～60KW, dry 2～20 hours;
The spray drying optimum range is chosen as intake air temperature: 150 ℃～350 ℃, and the air outlet temperature: 70 ℃～95 ℃, spray velocity: 1～300ml/min.
Below experiment all gets by the salvianolic acid A compositions sample that embodiment 3 preparation methoies obtain; The salvianolic acid A monomeric compound, commercially available, salvianolic acid A content is more than 99.62%.
Experimental example 12: the protective effect of salvianolic acid A compositions to the reperfusion injury of SD isolated rat heart
Male SD rat, body weight (280 ± 20) g; Quality certification SCXK (capital) 2007-0006 is provided by Beijing Vital River Experimental Animals Technology Co., Ltd..Open rapidly breast after intraperitoneal anesthesia, mention gently heart, decoct disconnected superior and inferior vena cava, pulmonary artery, aorta and heart tissue on every side, rapidly heart is taken out together with one section aorta, aortic root retains the approximately length of 0.5～1cm, and standby heart cathetrization is used.Move to immediately containing in oxygen K-H liquid (4 ℃ of left and right) of getting ready in advance, push gently heart intraventricular residual blood is discharged, clean the heart remained blood, hang on the Langendorff perfusion device, heart aorta ascending branch is connected on the sleeve pipe of perfusion, and fixes with the cotton thread ligation.Immediately containing oxygen K-H liquid, constant temperature (37 ± 0.5) ℃, to carry out perfusion; Perfusion pressure 70mm mercury column, flow velocity (11.5 ± 0.5) ml/min.K-H liquid composition (g/L): NaCl:6.9025; KCl:0.3517; CaCl 2: 0.2837; Anhydrous MgSO 4: 0.1424; KH 2pO 4: 0.1611; NaHCO 3: 2.0916; Glu:2.0837; Adjust pH 7.4.Cut an osculum at the left atrium sidewall, little latex water pocket is inserted to left ventricle by atrioventricular orifice.The latex water pocket is full of ultra-pure water with in the conduit be connected, and the other end of conduit, by the T joint pressure transducer, is thoroughly removed inner size bubble.The water yield of regulating water pocket in ventricle by the fine setting injector makes heart ventricle end diastolic pressure maintain the 4-6mmHg scope.Left indoor pressure is tested after stablizing 30min again.Record the coronary flow of each minute heart with graduated cylinder; Pressure transducer signal is inputted multitrack recording system by bridge amplifier, carries out the live signal acquisition and processing.
Experiment divides 7 groups: Normal group: to contain oxygen K-H liquid continous perfusion 120min; Model group: with containing after oxygen K-H liquid perfusion 15min, stop filling with 25min, then recover containing oxygen K-H liquid perfusion 60min; The high, medium and low dosage group of salvianolic acid A compositions (1.0,0.5,0.25mg/L), positive drug group (diltiazem hydrochloride 0.3mg/L), salvianolic acid A compositions monomeric compound group (0.5mg/L): use the pastille infusion liquid perfusion of variable concentrations when recovering perfusion, and continue whole refilling process.
Before each group record stops filling with and after filling with again since 10min, every maximum the climbing speed (+dp/dt of coronary flow (CBF), left ventricular diastolic pressure (LVEDP), left indoor pressure of 10min max) and the maximum fall off rate (dp/dt of left indoor pressure max), n=8.
Table 25. salvianolic acid A compositions on isolated rat heart pour into again the hemodynamic impact of 60min ( n=8)
Figure BSA00000811649200452
Annotate: with Normal group, compare: #P<0.01, ##P<0.001; With model group, compare: Δ P<0.05, * P<0.01, * * P<0.001
With Normal group, compare, model group ischemia-reperfusion 60min, CBF ,+dp/dt max,-dp/dt maxobviously descend (P<0.01 or P<0.001), LVEDP significantly increases (P<0.001).With model group, compare, positive drug group, the high, medium and low dosage group of salvianolic acid A compositions, salvianolic acid A monomeric compound group These parameters all have clear improvement, and can suppress the maximum climbing speed decline of coronary flow minimizing, the rising of left chamber diastolic pressure, left indoor pressure, the maximum fall off rate decline of left indoor pressure that ischemia-reperfusion causes.And salvianolic acid A compositions group high dose group is suitable with positive drug group effect, and effect is better than same dosage salvianolic acid A monomeric compound group.There is dose dependent between salvianolic acid A compositions various dose group.Experimental result shows that the salvianolic acid A compositions can alleviate isolated rat heart ischemical reperfusion injury degree, and prompting salvianolic acid A compositions can obviously be improved coronary flow, improve systolic and diastolic function, the cardioprotection ischemical reperfusion injury of isolated heart aorta diastolic function and damaged myocardium.
Experimental example 13: the impact of salvianolic acid A compositions on rats with myocardial ischemia electrocardio and cardiac function
Male SD rat, (250 ± 20) g, provided by Beijing Vital River Experimental Animals Technology Co., Ltd., quality certification SCXK (capital) 2007-0006.Animal is divided into model group, positive drug group (hydrochloride for injection diltiazem 1.5mg/kg), the high, medium and low dosage group of salvianolic acid A compositions (2.5,5.0,10.0mg/kg), salvianolic acid A monomeric compound group (5.0mg/kg) at random; Establish sham operated rats simultaneously.
20% urethane intraperitoneal anesthesia rat, fixing.Connect respirator after tracheal intubation, exhale by the frequency of 10～12ml tidal volume, 80 times/min, continuous positive pressure breathing, inhale: exhale than being 1: 1.Now connect electrocardiograph and measure the rat normal ECG.Open breast along between left border of sternum the 3rd, 4 ribs, extrude heart, find out left anterior descending coronary artery between left auricle and pulmonary conus, under the ramus descendens anterior arteriae coronariae sinistrae initial part, 2mm sentences circular noinvasive sewing needle 6-0 silk thread threading, rapid ligation ramus descendens anterior arteriae coronariae sinistrae (a sham operated rats not ligation of threading), and with a little plastics pipe pad with groove at the ligation position, the ligation thereon of two rear line heads, sew up thoracic wall, recover autonomous respiration.The complete Rat Ecg of at once observing of performing the operation, the left chamber antetheca of take be cyanosis and II lead electrocardiogram show the S-T section back of a bow upwards obviously raise and more than lasting 30min, be modeling successfully.
Each treated animal is tail vein injection relative medicine (sham operated rats and model group are injected isopyknic normal saline) after the modeling success, injects twice every day, continuously 7d.30min after the last administration, the animal intraperitoneal anesthesia, through the common carotid artery intubate to left ventricle, connect multiple tracks intelligence physiological signal acquisition analysis system by pressure converter, postoperative stable 30min, recorded heart rate (HR), arterial pressure, left ventricular systolic pressure (LVSP), maximum the climbing speed (+dp/dt of left indoor pressure max) and the maximum fall off rate (dp/dt of left indoor pressure max); Insert limb electrode monitoring standard II lead electrocardiogram simultaneously.
Table 26. salvianolic acid A compositions on the impact of rats with myocardial ischemia electrocardio and cardiac function (
Figure BSA00000811649200461
n=10)
Figure BSA00000811649200462
Figure BSA00000811649200471
Annotate: with sham operated rats, compare: #P<0.01; With model group, compare: * P<0.05, * * P<0.01
Experimental result shows, with sham operated rats relatively, following coronary artery occlusion causes the long-term myocardial infarction and ischemia model Rat Ecg of rat ST section and significantly improves (P<0.01), its HR, arterial pressure, LVSP ,+dp/dt max,-dp/dt maxall significantly descend (P<0.01), model group rat heart muscle contractile function obviously reduces.With model group, compare, after intravenously administrable 7d, each medicine group rat ST section obviously descends, every parameters of left ventricular function is improved in varying degrees (P<0.05 or P<0.01); And indices integrated display, with the middle and high dosage of salvianolic acid A compositions, the electrocardio of long-term rats with myocardial ischemia and parameters of left ventricular function are improved to effect in each medicine group the most obvious, be a certain amount of effect relationship between each dosage group of salvianolic acid A compositions, prompting salvianolic acid A compositions can reduce rats with myocardial ischemia ST section rising, improve heart rate, increase its arterial pressure, improve the cardiac muscle contracting power of relaxing, and effect is better than same dosage salvianolic acid A monomeric compound, electrocardio and the cardiac function of rats with myocardial ischemia improved significantly.
Experimental example 14: the impact of salvianolic acid A compositions on enzyme work and Radical Metabolism in rats with myocardial ischemia serum
Experimental example 13 is respectively organized rat after electrocardio and the end of parameters of left ventricular function mensuration, abdominal aortic blood, get serum, by the operation of detection kit description, measure superoxide dismutase (SOD), malonaldehyde (MDA) content and aspartate amino transferase (AST), creatine kinase (CK), lactic acid dehydrogenase (LDH) activity in serum.
Table 27. salvianolic acid A compositions is lived by enzyme in rats with myocardial ischemia serum and metabolism of free radical (
Figure BSA00000811649200472
n=10)
Annotate: with sham operated rats, compare: #P<0.01; With model group, compare: * P<0.05, * * P<0.01
Produce a large amount of oxygen-derived free radicals during myocardial ischemia, cardiac muscle is caused to damage, SOD, MDA are the objective indicators of reflection oxygen free radical injury; Extensively be present in myocardium enzyme AST, the LDH in myocardial cell, the activity of CK can reflect the degree of injury of myocardial ischemia.With sham operated rats relatively, in myocardial infarction and ischemia model group rat blood serum, SOD obviously reduces, MDA, AST, LDH, CK significantly raise (P<0.01); With model group relatively, after each Drug therapy, in administration group rat blood serum, SOD has rising in various degree, and MDA, AST, LDH, CK all obviously reduce (P<0.05 or P<0.01); And particularly remarkable with salvianolic acid A combination object height, middle dosage group and positive drug group drug effect.The experimental result prompting; the salvianolic acid A compositions can make SOD activity in rats with myocardial ischemia serum increase; suppress the generation of MDA, reduce AST, CK and LDH activity in serum, illustrate that the salvianolic acid A compositions can suppress oxygen-derived free radicals and produce; improve the oxidation resistance of cardiac muscular tissue; the protecting myocardial cell film, reduce overflowing of enzyme, improves myocardium energy supply; reduce ischemia to myocardium degree of injury, thereby play the ischemic myocardial protection effect.
Experimental example 15: the impact of salvianolic acid A compositions on the rats with myocardial ischemia myocardial infarct size
Get the rat after experimental example 14 blood sampling finishes, core immediately dirty, normal saline cleans, and cuts off right atrium, isolates left ventricle, claims the left ventricle weight in wet base after sucking excessive moisture.Below ligature, parallel coronary sulcus direction is cut into 5 of equal thickness, put into the 1%TTC dye liquor, 37 ℃ of constant temperature dyeing 10min, infarct is not dyed to redness, and infarct is not colored and is canescence, and infarct is weighed, calculate infarct and heavily account for the heavy percentage ratio of left ventricle, i.e. myocardial infarct size.
Table 28. salvianolic acid A compositions on the impact of rats with myocardial ischemia myocardial infarct size (
Figure BSA00000811649200481
n=10)
Figure BSA00000811649200482
Annotate: with sham operated rats, compare: #P<0.01; With model group, compare: * * P<0.01
Obvious myocardial ischemia infarction appears in myocardial infarction and ischemia model group rat, and infarction size reaches 53% left and right; With model group, compare, after various dose salvianolic acid A compositions drug administration by injection 7d, the myocardial infarct size of rat significantly reduces (P<0.01), and presents certain dose-effect relationship.Less than salvianolic acid A monomeric compound group rat myocardial infarction model scope with dosage salvianolic acid A compositions.Prompting salvianolic acid A compositions can be dwindled myocardial infarct size, alleviates treating myocardial ischemia damage and heart infarction degree, and myocardial ischemia is had to obvious therapeutic action.
。
Experimental example 16: the salvianolic acid A compositions is on rats with myocardial ischemia cardiac muscle histopathology and Ultrastructural impact
Animal model and grouping administration are with experimental example 13.Administration finishes rear second day, and sacrifice of animal, core dirty, and normal saline flushing, cut left ventricle, the left ventricle that each group is got Some Animals at random, and in 10% formaldehyde, after fixing, rinse, dewatering, dimethylbenzene soaks into, paraffin embedding, section, HE dyeing, mounting.Observe myocardium microstructure under light microscopic.Get the left ventricle of random residual animal, fixing in 3% glutaraldehyde solution, through dehydrations at different levels, with expoxy propane, soak into epoxy resin Epon812 embedding, 65 ℃ of polymerizations, section, electron microscopic observation Myocardial ultrastructure.
Result shows, observes sham operated rats animal cardiac muscle marshalling under light microscopic, and the heart band is clear, and extremely indivedual slight hypertrophy of flesh core are only arranged, and myocardium interstitial has no cell infiltration, without hemorrhagic necrosis.Model group and sham operated rats compare, cardiac muscle fiber obvious tumefaction, degeneration, and arrangement disorder, cardiac muscle cross striation is most of to disappear, the obvious hypertrophy of flesh core, the fine red hypertrophy of spatium intermusculare is more, a large amount of cell infiltration, the necrosis of part specimen cardiac muscular tissue, the dissolved sample of muscle glycogen, have obvious kitchen range shape myocardial infarction.Various dose salvianolic acid A compositions group, positive drug (hydrochloride for injection diltiazem) group and salvianolic acid A monomeric compound group and model group are relatively; pathological changes all obviously alleviates; the cardiac muscle fiber mild swelling; arrange still orderly; band is more clear, the slight hypertrophy of flesh core, and myocardium interstitial is without hemorrhage; the inflammatory cell infiltration do not waited is on a small quantity arranged, and salvianolic acid A compositions low dose group and salvianolic acid A monomeric compound group only indivedual animal cardiac muscles are slight degeneration; Paired observation between each treatment group, salvianolic acid A combination object height, middle dosage and the cardiac muscle swelling of positive drug group and inflammatory infiltration are the lightest, and ischemic myocardial tissue is had to more obvious protective effect.
Observe visible sham operated rats animal cardiac muscle cell Z line rule under transmission electron microscope, each muscle segment is clear, and myofilament is evenly distributed, arranges closely neat, and triplet is obvious, and structure of mitochondria is complete, and ridge is many, clear and arrange orderly.Model group and sham operated rats compare, sarcostyle arrangement disorder, and visible downright bad muscle fiber, and mitochondrion obviously increases, vacuolar degeneration, ridge rareness or fall into disarray, and unintelligible, muscle segment shortens, structure disturbance, myofilament fracture, downright bad or dissolving; The nuclear membrane structure is discontinuous, and pathological change is fairly obvious.Salvianolic acid A compositions low dose group and salvianolic acid A monomeric compound group structure of mitochondria are substantially complete, the part mitochondrial vacuolar degeneration, and myofilament is arranged still neat, and the part ridge is smudgy, and Ultrastructural change obviously is lighter than model group; Salvianolic acid A combination object height, middle dosage group, positive drug group myocardial cell Z line fundamental rule, substantially complete, the few part mitochondrial swelling of structure of mitochondria, ridge is substantially clear, and myofilament is arranged substantially neat, the nucleus structural integrity, the ultrastructure shows pathological changes is obviously improved.
Light microscopic and Electronic Speculum results suggest, the salvianolic acid A compositions can obviously be improved the myocardium pathological change of rats with myocardial ischemia, alleviates myocardium pathology damage, can be used for the treatment of ischemic heart desease.And action effect is than more obvious with the salvianolic acid A monomeric compound of dosage.
Experimental example 17: the impact of salvianolic acid A compositions on Myocardial Ischemia Reperfusion Injury SD rat myocardial infarction model scope
Male SD rat, (280 ± 20) g is divided into 7 groups at random: sham operated rats, model group, hydrochloride for injection diltiazem group (1.5mg/kg), the high, medium and low dosage group of salvianolic acid A compositions (10.0,5.0,2.5mg/kg), salvianolic acid A monomeric compound group (5.0mg/kg).
20% urethane intraperitoneal anesthesia rat, fixing.Connect respirator after tracheal intubation, exhale by the frequency of 10～12ml tidal volume, 80 times/min, continuous positive pressure breathing, inhale: exhale than being 1: 1.Now connect electrocardiograph and measure the rat normal ECG.Open breast along between left border of sternum the 3rd, 4 ribs, extrude heart, between boring admittedly, left auricle and pulmonary artery find out left anterior descending coronary artery, under the ramus descendens anterior arteriae coronariae sinistrae initial part, 2mm sentences circular noinvasive sewing needle 6-0 silk thread threading, rapid ligation ramus descendens anterior arteriae coronariae sinistrae (a sham operated rats not ligation of threading), and with a little plastics pipe pad with groove at the ligation position, the ligation thereon of two rear line heads, recording ecg.The left chamber antetheca of take be cyanosis and II lead electrocardiogram show the S-T section back of a bow upwards obviously raise and more than lasting 20min, be modeling successfully; After myocardial ischemia 90 minutes, unclamp line, take out pipe pad, realize pouring into again.Close breast, sew up, recover autonomous respiration.Ligation tail vein injection administration at once (sham operated rats and model group give isometric normal saline), after this every 2h, be administered once, administration is 4 times altogether; In batches after filling with again 6h, 24h, 48h anesthetized animal (fill with again 24,48h treated animal second day after 4 administrations on the operation same day finish begins still twice of drug administration by injection every day, until draw materials), fixing, cut open breast and core dirty, separate left ventricle, claim the left ventricle weight in wet base after sucking excessive moisture.Below ligature, crosscut becomes 5 of equal thickness, puts into the 1%TTC dye liquor, 37 ℃ of constant temperature dyeing 10min, infarct is not dyed to redness, and infarct is not colored and is canescence, infarct is weighed, and calculates infarct and heavily accounts for the heavy percentage ratio of left ventricle, i.e. myocardial infarct size.
Table 29. salvianolic acid A compositions on the impact of myocardial ischemia in rats-fill with again different time myocardial infarct size (
Figure BSA00000811649200501
n=6)
Figure BSA00000811649200511
Annotate: with sham operated rats, compare: #P<0.01; With model group, compare: * * P<0.01
Model group myocardial ischemia in rats 1.5h, then after pouring into 6h, myocardial infarction is serious, and in recovering perfusion 48h, infarction size progressively increases, the myocardial damage aggravation.With model group, compare, various dose salvianolic acid A compositions can obviously be dwindled myocardial infarct size (P<0.01), alleviate the myocardial ischemia-reperfusion damage, and myocardial infarct size does not enlarge with the Ischemia Reperfusion time lengthening; There is certain agent effect relationship between each dosage group, and be better than same dosage salvianolic acid A monomeric compound.Prompting salvianolic acid A compositions can be dwindled the myocardial infarct size that expeirmental myocardial ischemia pours into rat again, alleviates Myocardial injury degree, and Myocardial Ischemia Reperfusion Injury is had to preventive and therapeutic effect preferably.
Experimental example 18: the impact of salvianolic acid A compositions on Myocardial Ischemia Reperfusion Injury SD metabolism of free radicals in rats
Modeling and medication are with experimental example 17.After recovering to pour into 24h again, Animal Anesthesia, core dirty, cut off atrium, retain ventricle, the ice normal saline flushing, blot surface moisture, weigh, make tissue homogenate, centrifugal (3000rpm, 10min), get supernatant, according to the operation of test kit description, detect malonaldehyde (MDA) content, superoxide dismutase (SOD), xanthine oxidase (XOD), glutathion peroxidase (GSH-Px), catalase (CAT) activity in tissue.
The impact that table 30. salvianolic acid A compositions is lived on Radical Metabolism relevant enzyme in rat tissue (
Figure BSA00000811649200512
n=10)
Figure BSA00000811649200521
Annotate: with sham operated rats, compare: #P<0.01; With model group, compare: * P<0.05, * * P<0.01
Experimental result shows, with sham operated rats, compare, the model group rat is at ischemia-reperfusion 24h, the SOD of cardiac muscular tissue, GSH-Px, CAT enzyme are lived and are significantly descended, MDA, XOD enzyme are lived and are significantly raise (P<0.01), and the prompting myocardial ischemia in rats-after pouring into, Peroxidation Product is piled up serious again, myocardial clearance Peroxidation Product ability significantly descends, and Ischemia Reperfusion causes that a large amount of oxygen-derived free radicals generations cause myocardial damage to increase the weight of.Each medicine group and model group compare, and the SOD of cardiac muscular tissue, GSH-Px, CAT enzyme are lived and raise in various degree, and MDA, XOD enzyme are lived and reduced in various degree (P<0.05 or P<0.01), and salvianolic acid A combines object height, middle dosage group effect is the most obvious.The prompting salvianolic acid A can strengthen myocardial clearance free radical ability, suppresses oxygen-derived free radicals and produces, and strengthens the rat heart muscle oxidation resistance, suppresses Myocardial Ischemia Reperfusion Injury.
Experimental example 19: salvianolic acid A and the compound impact on dog Myocardial Ischemia Reperfusion Injury degree of myocardial ischemia
Healthy dogs, (17.5 ± 2.5) kg is divided into 6 groups immediately: be respectively model group, hydrochloride for injection diltiazem table group (0.5mg/kg), the high, medium and low dosage group of salvianolic acid A compositions (6,3,1.5mg/kg), salvianolic acid A monomeric compound group (3mg/kg).Pentobarbital sodium 30mg/kg intravenous injection anesthesia, fixing, tracheal intubation connects respirator, separates left carotid, the intubate recording blood pressure that is connected with polygraph through pressure transducer, separation right side external jugular vein, along left side, the 4th intercostal is opened breast, makees the pericardium bed.Separate aortic arch, place the electromagnetic flowmeter probe, measure cardiac output.After opening breast, intubate is to right ventricle, the records center venous pressure.Separate M-LAD, the standby ligation use of lead-in wire, seam is put 16 epicardial leads of leading and is connected ecg amplifier, records the visceral pericardium electrocardiogram.Apex of the heart intubate, the Bonding pressure transducer, measure intraventricular pressure.Record indices stable after, adopt two step ligation method ligation arteria coronaria left anterior descending branches.2min before ligation first, give 2.5mg/kg lignocaine prevention arrhythmia.Stablize 15min after Complete Ligation, the femoral vein constant speed is injected administration, administration volume 1ml/kg, and the 10min injection is complete.Model group and sham operated rats wait the normal saline of capacity.After ischemia 3h, the solution bolt that bursts at the seams, realize pouring into again.Respectively before ligation, ligation 15min (before being administration), 30,60,120,180min, fill with 30min again, fill with the variation that 60min records the visceral pericardium ECG ST section, blood oxygen again.Mean the myocardial ischemia journey with each total mV number (∑-ST) that ST section of each mapping point raises constantly.
Table 31. salvianolic acid A compositions on the impact of dog Myocardial Ischemia Reperfusion Injury degree of myocardial ischemia (∑-ST) (
Figure BSA00000811649200531
mV, n=6)
Annotate: with sham operated rats, compare: #P<0.001; With model group, compare: * P<0.05, * * P<0.01
The experimental result demonstration, after ligation dog coronary artery, 5min starts, and each is organized dog epicardial electrogram ST section and raises obviously rising of sum (∑-ST); The model group dog has been elevated to a metastable level to 15min after ligation, and after realizing perfusion again, although ∑-ST than descending between ischemic stage, significantly increases (P<0.001) with sham operated rats, prompting dog cardiac muscle is still in ischemic state.In the 15min of each medicine group before ligation and after ligation (before being administration), each organizes ∑-ST and model group does not relatively have diversity (P>0.05); And after ligation 30min begin (being 15min after administration), each medicine group ∑-ST starts to descend, degree of ischemia alleviates, but (P<0.05) notable difference is relatively arranged except salvianolic acid A compositions high dose group and model group, and the other medicines group descends does not have statistical significance; But, after to 60min after ligation to ligation during 180min (be after administration 45min to during 165min after medicine), each medicine group ∑-ST is continuous decrease still, and with model group, significant difference (P<0.05 or P<0.01) is more all arranged; After recovering perfusion again, each medicine group ∑-ST and model group significantly reduce.Have a certain amount of effect relationship between each dosage group of salvianolic acid A compositions, in the salvianolic acid A compositions, dosage group ∑-ST fall is suitable with 0.5mg/kg hydrochloride for injection diltiazem group, and slightly excellent trend is arranged.The salvianolic acid A compositions descends more obvious than the ∑ with dosage salvianolic acid A monomeric compound group-ST.Prompting salvianolic acid A compositions can alleviate the degree of myocardial ischemia of experiment ischemia-reperfusion dog, and effect is better than same dosage salvianolic acid A monomeric compound.Point out it to damage by Ischemic myocardium, ischemic heart desease is had to good therapeutical effect.
Experimental example 20: the impact of salvianolic acid A compositions on dog Myocardial Ischemia Reperfusion Injury myocardial ischemia scope
Modeling, the grouping administration described with experimental example 19.Record the variation of the visceral pericardium ECG ST section of each time period of each treated animal, with each moment, the mapping point sum (N-ST) of ST section rising >=2mV means the myocardial ischemia scope.
Table 32. salvianolic acid A compositions on the impact of dog Myocardial Ischemia Reperfusion Injury myocardial ischemia scope (N-ST) ( n=6)
Figure BSA00000811649200542
Annotate: with sham operated rats, compare: #P<0.001; With model group, compare: * P<0.05, * * P<0.01
The experimental result demonstration, after ligation dog coronary artery, each organizes dog epicardial electrogram N-ST obviously increases; The model group dog is to 15min after ligation, and N-ST has been increased to a metastable level, and the ischemia scope is basicly stable, and after realizing perfusion again, although N-ST reduces during than ligation, but still the utmost point is significantly higher than sham operated rats (P<0.001).In the 15min of each medicine group before ligation and after ligation (before being administration), each organizes N-ST and model group does not relatively have diversity; And after ligation 30min begin (being 15min after administration), each medicine group N-ST starts to have the trend of minimizing, but except salvianolic acid A compositions high dose group slip and model group relatively have (P<0.05) notable difference, other medicines group no difference of science of statistics; But, after to 60min after ligation to ligation during 180min (be after administration 45min to during 165min after medicine), each medicine group N-ST still continues to reduce, and with model group, significant difference (P<0.05 or P<0.01) is more all arranged; After recovering perfusion again, each medicine group N-ST and model group significantly reduce.There is a certain amount of effect relationship between each dosage group of salvianolic acid A compositions, in the salvianolic acid A compositions, dosage group N-ST slip is suitable with 0.5mg/kg hydrochloride for injection diltiazem group, and the salvianolic acid A compositions reduces obviously than the N-ST with dosage salvianolic acid A monomeric compound group.Prompting salvianolic acid A compositions can reduce the myocardial ischemia scope of experiment ischemia-reperfusion dog, and effect is better than same dosage salvianolic acid A monomeric compound.Point out it to damage by Ischemic myocardium, ischemic heart desease is had to good therapeutical effect.
Experimental example 21: the impact of salvianolic acid A compositions on dog Myocardial Ischemia Reperfusion Injury myocardial infarct size
Modeling, the grouping administration described with experimental example 19.Each organizes dog ischemia 180min, then, after pouring into 60min, cores dirty, normal saline flushing, and weighing is heavy whole-heartedly.Cut off trunk and atrium, satisfactory chamber is heavy, from the apex of the heart to ligation point, on average is cut into five, O.5% in nitro blue tetrazolium (N-TB) dye liquor, dye, and 15min, infarcted region is not painted, and non-infarcted region is dyed skipper.Separate infarcted region and non-infarcted region and weigh, accounting for heavy, infarcted myocardium whole-heartedly with infarcted myocardium and account for the percentage calculation infarction size that ventricle is heavy.
Table 33. salvianolic acid A compositions on the impact of dog Myocardial Ischemia Reperfusion Injury myocardial infarct size ( n=6)
Figure BSA00000811649200552
Annotate: with sham operated rats, compare: #P<0.01; With model group, compare: * P<0.05, * * P<0.01
The experimental result demonstration, after model group dog ischemia-reperfusion, myocardial infarction is heavier.Salvianolic acid A compositions, hydrochloride for injection diltiazem, salvianolic acid A monomeric compound all can significantly reduce the experimental dog myocardial infarct size, and, with salvianolic acid A compositions high dose group dog myocardial infarction ratio minimum, in the salvianolic acid A compositions, dosage group myocardial infarct size is less than same dosage salvianolic acid A monomeric compound group.With model group, compare; salvianolic acid A combination object height, middle dosage group can extremely significantly reduce the proportion (P<0.01) that infarcted myocardium accounts for heart and ventricle; the proportion that salvianolic acid A compositions low dosage dog myocardial infarction district accounts for heart and ventricle also obviously reduces (P<0.05); prompting salvianolic acid A compositions energy dose dependent ground dwindles the experimental dog myocardial infarct size; energy Ischemic myocardium-reperfusion injury, be used for the treatment of ischemic heart desease.And effect is better than same dosage salvianolic acid A monomeric compound.
Experimental example 22: the impact of salvianolic acid A compositions on the dogs with acute myocardial ischemia coronary flow
Modeling, grouping, administration time and dosage are with the described method of experimental example 19.After animal opens breast, separate LCA, place the electromagnetic flowmeter probe, different time sections heart coronary flow (CBF) in ischemic stage 240min before measuring ligation, after ligation.Put to death animal after experiment finishes, using 1/3rd heart weight as LC drain district, calculate the blood flow of every 100g cardiac muscle: MBF=(CBF/ cardiac weight) * 100 * 3.
Table 34. salvianolic acid A compositions on the impact of Myocardial Ischemia Reperfusion Injury dog coronary flow ( n=6)
Figure BSA00000811649200562
Annotate: after administration, blood flow amplification with model group amplification relatively: * P<0.05, * * P<0.01
The experimental result demonstration, each time period coronary flow of sham operated rats dog does not have significant change; From before each time period coronary flow of model group dog and ligation relatively and respectively organize comparative result before coronary flow before the dog administration and ligation, after ligation dog coronary artery forms myocardial ischemia, coronary flow has the short time compensatory to increase, and increasing degree is in 10% left and right; Before each time period coronary flow and administration, increase is in various degree relatively arranged after each dosage of salvianolic acid A compositions, hydrochloride for injection diltiazem, each administration of salvianolic acid A monomeric compound treatment group dog, each medicine group is 15min (being ligation 30min) after administration, coronary flow amplification is between 13%～24%, except salvianolic acid A high dose group amplification has notable difference, other each medicine groups increase and are not obvious; And after administration, 45min, to 225min (being ligation 60min to 240min) after administration, relatively, has increased between 25.3%～52.6% before each medication therapy groups coronary flow and administration; The most remarkable with salvianolic acid A combination object height, middle dosage group, hydrochloride for injection diltiazem group, amplification is respectively 52.6%, 40.2%, 36.7%.In the salvianolic acid A compositions, dosage group amplification is higher than same dosage salvianolic acid A monomeric compound group.Prompting salvianolic acid A compositions can promote collateral circulation open, the coronary flow while increasing myocardial ischemia, thus to resisting myocardial ischemia, the Ischemic myocardium damage, point out it aspect control ischemic heart desease, certain purposes being arranged.
Experimental example 23: the salvianolic acid A compositions is on myocardial ischemia dog cardiac function and hemodynamic impact
The described method of experimental example 19 is pressed in modeling, grouping administration; Aortic root is placed the electromagnetic flowmeter probe, measures cardiac output (CO); Apex of the heart intubate is to left ventricle, and the Bonding pressure transducer, measure left constant pressure, left indoor pressure maximum collapse and diastole rate of change (± dp/dt max); Recording ecg (ECG); Stablize the 15min administration after the coronary ligation operation; Polygraph record, the variation of measuring and calculating interior each leading indicator of different time of dog ischemia 240min: CO, left ventricular end diastolic presssure (LVEDP), ± dp/d tax, the acting of left chamber (LVW), total peripheral resistance (TPR).
Table 35. salvianolic acid A compositions on the impact of myocardial ischemia dog CO (
Figure BSA00000811649200571
l/min, n=6)
Annotate: with before self ischemia relatively, #P<0.05, ##P<0.01; Compare * P<0.05, * * P<0.01 with model group
Table 36. salvianolic acid A compositions on the impact of myocardial ischemia dog LVEDP ( mmHg, n=6)
Figure BSA00000811649200574
Annotate: with before self ischemia relatively, #P<0.05, ##P<0.01; Compare * P<0.05, * * P<0.01 with model group
Table 37. salvianolic acid A compositions is to myocardial ischemia dog+dp/dt maximpact ( mmHg/s, n=6)
Figure BSA00000811649200583
Annotate: with before self ischemia relatively, #P<0.05, ##P<0.01; Compare * P<0.05, * * P<0.01 with model group
Table 38. salvianolic acid A compositions is to myocardial ischemia dog one dp/dt maximpact (
Figure BSA00000811649200584
mmHg/s, n=6)
Figure BSA00000811649200585
Annotate: with before self ischemia relatively, #P<0.05, ##P<0.01; Compare * P<0.05, * * P<0.01 with model group
Table 39. salvianolic acid A compositions on the impact of the left chamber of myocardial ischemia dog acting (LVW) (
Figure BSA00000811649200586
n=6)
Figure BSA00000811649200591
Annotate: with before self ischemia relatively, #P<0.05, ##P<0.01; Compare * P<0.05, * * P<0.01 with model group
Table 40. salvianolic acid A compositions on the impact of myocardial ischemia dog total peripheral resistance (TPR) (
Figure BSA00000811649200592
n=6)
Figure BSA00000811649200593
Annotate: with before self ischemia relatively, #P<0.05, ##P<0.01; Compare * P<0.05, * * P<0.01 with model group
Experimental result shows, after ligation coronary ischemia 30min, before dog cardiac output (CO) and ischemia, significantly descend, LVEDP significantly raises, ± dp/dt maxsignificantly decline, left chamber acting (LVW) reduce, total peripheral resistance (TPR) enlarges markedly (P<0.05 or P<0.01), after the dog coronary ligation is described, myocardial function is impaired obviously, myocardial contraction and diastolic function descend, hypokinemia, cardiac pumping function reduces, blood oxygen supply deficiency, and the impaired cardiac function that causes of myocardial ischemia-anoxemia descends.With model group, compare: 15min after the administration of high dose salvianolic acid A compositions (being ischemia 30min) can significantly suppress LVEDP rising, inhibition ± dp/dt maxdescend, suppress dog LVW reduction TPR, 45min after administration (after being ischemia 60min) can significantly suppress CO and descend; 15min (after the ischemia 30min) dog ± dp/dt that can raise after the administration of middle dosage salvianolic acid A compositions max, TPR is descended, 45min after administration (after being ischemia 60min) can significantly suppress dog LVW reduction LVEDP, increases 105min (being ischemia 120min) dog CO after administration, its action effect is suitable with the hydrochloride for injection diltiazem; After the administration of salvianolic acid A compositions low dose group, 105min can obviously suppress dog CO decline, and after administration, 45min can reduce dog TPR, rising ± dp/dt maxand increase LVW, and after administration after 105min (being ischemia 120min) can obviously reduce dog LVEDP, and the trend that is better than same dosage salvianolic acid A monomeric compound is arranged.After the administration of results suggest salvianolic acid A compositions, can improve myocardial ischemia dog hemodynamic index, the myocardial contraction of Enhancement test dog, improve myocardium systolic and diastolic function, reduce Peripheral resistance, suppress the blood-pumping function that cardiac output reduces, improves heart, improve the myocardial blood supply, improve myocardial ischemia and cardiac function, the performance function of resisting myocardial ischemia.
Experimental example 24: the impact of salvianolic acid A compositions on myocardial ischemia dog myocardium enzyme
Modeling, grouping administration are with the described method of experimental example 19.Administration after the postoperative stable 15min of coronary ligation, after ligation, 240min (being 4h after ischemia) gets blood from femoral vein respectively, detects creatine kinase (CK), lactic acid dehydrogenase (LDH), aspartate aminotransferase (AST), creatine kinase isozyme (CK-MB) in serum.
Table 41. salvianolic acid A compositions on the impact of myocardial ischemia dog myocardium enzyme (
Figure BSA00000811649200601
u/L, n=6)
Figure BSA00000811649200602
Annotate: compare * P<0.01, * * P<0.001 with model group
In serum, CK, LDH, AST, CK-MB are the myocardial zymetology of the coherent detection as Hypoxicichemic myocardial lesion commonly used clinically, but the reflecting myocardium degree of injury.Wherein CK-MB is the Cardiac-specific enzyme, the most responsive in myocardial damage.Experimental result shows, with sham operated rats, compares, and in myocardial infarction and ischemia model group dog serum, CK, LDH, AST, CK-MB significantly raise, after the ligation coronary ischemia is described, the dog myocardial mitochondria is destroyed, myocardial cell injury, and myocardium enzyme is released the rising alive of the clear center of hyperamization creatase.Each dosage group of salvianolic acid A compositions and model group relatively, can reduce to some extent after dog myocardial ischemia 4h CK, LDH, AST, CK-MB active (P<0.01 or P<0.001) in serum, and be dose dependent; Middle dosage salvianolic acid A compositions group ratio is with dosage salvianolic acid A monomeric compound group more remarkable effect.Experimental result prompting salvianolic acid A compositions can be stablized myocardial cell membrane, and the overflowing of myocardium enzyme during the minimizing treating myocardial ischemia damage, have obvious protective effect to ischemic myocardium.
Experimental example 25: the impact of salvianolic acid A compositions on myocardial ischemia dog fatty acid metabolism and radical metabolism
Modeling, grouping administration are with the described method of experimental example 19.Administration after the postoperative stable 15min of coronary ligation, after ligation, 240min (being 4h after ischemia) gets blood from femoral vein respectively, detects serum free fatty acid (FFA), lipid peroxide (LPO), malonaldehyde (MDA) content, superoxide dismutase (SOD), glutathion peroxidase (GSH-Px).
Table 42. salvianolic acid A compositions on the impact of myocardial ischemia dog fatty acid metabolism and radical metabolism (
Figure BSA00000811649200611
n=6)
Annotate: compare * P<0.05, * * P<0.01 with model group
Can cause during myocardial ischemia that disorder in various degree appears in a series of myocardial metabolisms, thereby cause cardiac insufficiency.The main reason for the treatment of myocardial ischemia damage is owing to causing the Power supply obstacle to make myocardial damage even downright bad after myocardial ischemia.Free fatty is the main substrate of normal heart energy supply.And cardiac muscle is under ischemia, because the fatty acid oxidation energy supply will consume more oxygen than glucose metabolism energy supply, myocardial ischemia phase free fatty acid levels and oxygenation efficiency raise and can suppress the oxidation of glucose, increase the gathering of lactic acid in cell, therefore can make the Efficiency Decreasing of heart acting, cardiac muscle is produced to adverse influence.Experimental result shows, with sham operated rats, compare, the model group dog is after ischemia 4h, the significantly rising (P<0.01) of serum free fatty acid (FFA), lipid peroxide (LPO), after the prompting myocardial ischemia, obstacle appears in the Myocardial Fatty Acids metabolism, the activity that will suppress the glucose oxidase Major Enzymes, thus myocardial oxygen consumption increased, enlarge myocardial infarct size.And each dosage group of salvianolic acid A compositions and model group are relatively, can significantly reduce FFA in the myocardial ischemia dog serum, LPO content (P<0.05 or P<0.01), and be dose-dependence.Prompting salvianolic acid A compositions can significantly suppress FFA level in serum and raise, and improves the Myocardial Fatty Acids metabolism, reduces the accumulation of lactic acid; increase the production capacity of unit oxygen consumption, reduce myocardial oxygen consumption, thereby improve cardiac function; suppress myocardial infarct size, the Ischemic myocardium damage.
With sham operated rats, compare, after model group dog myocardial ischemia 4h in serum MDA content significantly raise, active significantly descend (P<0.01) of SOD, GSH-Px, after prompting dog myocardial ischemia, oxygen-derived free radicals generates obviously to be increased, remove the enzyme significantly reduction alive of oxygen-derived free radicals in body, and oxygen-derived free radicals can affect by a series of oxidation reactions normal configuration and the function of cell, aggravation treating myocardial ischemia damage degree.Each dosage group of salvianolic acid A compositions and model group relatively, can significantly reduce the content of MDA in the myocardial ischemia dog serum, make the active obviously enhancing (P<0.05 or P<0.01) of SOD in serum, GSH-Px simultaneously, and are certain agent effect relationship; Prompting salvianolic acid A compositions can suppress the lipid peroxidation process by certain mechanism, reducing oxygen-derived free radicals generates, simultaneously can improve the endogenous activities of antioxidant enzymes again and alleviate oxygen-derived free radicals to myocardium damage, improving the oxidation resistance of ischemic myocardium and bring into play function of resisting myocardial ischemia.And effect is better than same dosage salvianolic acid A monomeric compound.
Experimental example 26: the impact of salvianolic acid A compositions on myocardial ischemia dog myocardial oxygen consumption
Prepare myocardial ischemia dog: modeling, grouping, to medicament in time between with the described method of experimental example 19.Through the external jugular vein intubate to coronary sinus vein, in the carotid artery intubate, with the Oximetry instrument respectively before the ligation arteria coronaria and after ischemia 15,30,60,120,240min measures the Coronary vein of each animal, the oxygen content of tremulous pulse, calculating myocardium oxygen consumption and coefficient of oxygen utilization.Myocardial oxygen consumption=(carotid artery blood oxygen amount-coronary sinus vein blood oxygen amount) * CBF; Cardiac muscle coefficient of oxygen utilization=(carotid artery blood oxygen amount-coronary sinus vein blood oxygen amount)/carotid artery blood oxygen amount * 100%.
Table 43. salvianolic acid A compositions on the impact (ml/min) of myocardial ischemia dog myocardial oxygen consumption (
Figure BSA00000811649200621
n=6)
Figure BSA00000811649200622
Figure BSA00000811649200631
Annotate: compare * P<0.05, * * P<0.01 with model group
Table 44. salvianolic acid A compositions on the impact (%) of myocardial ischemia dog cardiac muscle coefficient of oxygen utilization (
Figure BSA00000811649200632
n=6)
Figure BSA00000811649200633
Annotate: compare * P<0.05, * * P<0.01 with model group
Oxygen metabolism imbalance, oxygen supply and aerobic imbalance are the main causes of myocardial ischemia.Experimental result shows, the model group dog is after the ligation arteria coronaria causes myocardial ischemia, relatively there is no significant change before myocardial oxygen consumption and coefficient of oxygen utilization and ischemia, but the experiment in conjunction with aforementioned relevant myocardial ischemia left chamber acting in this explanation is known, after myocardial ischemia, the acting of left chamber reduces, and myocardial oxygen consumption and coefficient of oxygen utilization unchanged, therefore, the oxygen consumption of unit acting increases, and the heart mechanical efficiency significantly reduces.With model group, compare, the salvianolic acid A compositions of various dose can reduce myocardial oxygen consumption and coefficient of oxygen utilization to some extent, and wherein salvianolic acid A combination object height, middle dosage group ischemia 120min (being 105min after administration) coefficient of oxygen utilization have reduced respectively nearly 20%, 16% before than administration.In conjunction with the experimental result of relevant salvianolic acid A compositions to parameters of left ventricular function such as myocardial ischemia dog coronary flow and ventricle actings in this explanation; prompting salvianolic acid A compositions can reduce myocardial oxygen consumption and coefficient of oxygen utilization; improve the equilibrium of supply and demand of myocardium oxygen; improve ventricular function; the effect of performance protection ischemic myocardium, the control myocardial ischemia.
Experimental example 27: the salvianolic acid A compositions is on the hemorheological impact of myocardial ischemia dog
Prepare myocardial ischemia dog: modeling, grouping, dosage and time are with the described method of experimental example 19.Draw blood after ischemia 240min respectively, carry out the mensuration of the hemorheology indexs such as whole blood viscosity, plasma viscosity, plasma fibrinogen content, packed cell volume, platelet adhesion rate.
Table 45. salvianolic acid A compositions on the impact of myocardial ischemia dog whole blood viscosity, plasma viscosity (
Figure BSA00000811649200641
n=6)
Figure BSA00000811649200642
Annotate: compare * P<0.05 with model group
With sham operated rats, compare, whole blood viscosity, plasma viscosity that the ligation arteria coronaria causes the myocardial ischemia dog obviously raise, and plasma fibrinogen content obviously rises, and packed cell volume and platelet adhesion rate obviously increase (P<0.05); With model group, compare, in experiment, various dose salvianolic acid A compositions can make myocardial ischemia dog blood viscosity, plasma viscosity, packed cell volume and platelet adhesion rate reduce to some extent, obviously reduces fiber protein content in blood plasma; Be certain agent effect trend between each dosage group; Prompting salvianolic acid A compositions can reduce blood viscosity, suppresses platelet adhesion and assembles, and the prevention Intravascular Thrombus forms, and improves myocardial ischemia dog hemorheology, improves microcirculation, can be for preventing and treating ischemic heart desease.
Experimental example 28: the impact that the salvianolic acid A compositions forms the rat thrombus in vivo
The SD rat, (280 ± 20) g, random minute 6 groups: normal saline group matched group, the high, medium and low dosage of salvianolic acid A compositions (20,10,5mg/kg) group, aspirin group (10mg/kg), salvianolic acid A monomeric compound group (10mg/kg).Each organizes tail vein injection administration every day 1 time (matched group gives the isometric(al) normal saline), continuous 7d, 1h after the last administration, pentobarbital sodium (40mg/kg) anesthetized rat, dorsal position is fixed, and right common carotid artery and left external jugular vein are isolated in operation, with three sections polyethylene tubes, connects.Put into the long 5cm operation silk thread of having weighed in the polyethylene tube stage casing.Be full of polyethylene tube with heparin-saline solution (5u/mL).One end of pipe inserts left external jugular vein, and the other end is connected with right common carotid artery.Open bulldog clamp, blood returns to left jugular vein by the right carotid polyethylene tube of flowing through.Herba Clinopodii in after open blood flow 15min, take out rapidly silk thread, and filter paper sucks supernatant blood, weighs, and gross weight subtracts line and heavily obtains wet weight of thrombus; Then put in 60 ℃ of baking ovens freeze-day with constant temperature to constant weight, weigh after cooling, be the thrombosis dry weight.
The impact that table 46. salvianolic acid A compositions forms the rat thrombus in vivo (
Figure BSA00000811649200651
n=6)
Figure BSA00000811649200652
Annotate: compare * P<0.05, * * P<0.01 with the normal saline group
With the normal saline group relatively, 60,30,15mg/kg salvianolic acid A compositions can significantly alleviate that rat suppository is wet, dry weight (P<0.05 or P<0.01), and thrombosis is had to obvious inhibitory action; Be certain dose-effect relationship between each dosage group, and inhibition is better than same dosage salvianolic acid A monomeric compound.Prompting salvianolic acid A compositions has and suppresses the effect that the rat thrombus in vivo forms, and points out it to can be used for preventing and treating the ischemic heart desease due to thrombosis.

Claims (35)

1. a salvianolic acid A compositions is for the preparation of the purposes of preventing and treating the ischemic heart medicine, and said composition is comprised of salvianolic acid A, alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C; Wherein
The molecular formula of described salvianolic acid A: C 26h 22o 10, molecular weight: 494.45, structure is as follows:
Figure FSA00000811649100011
The molecular formula of described alkannic acid: C 27h 22o 12, molecular weight: 538.46, structure is as follows:
Figure FSA00000811649100012
The molecular formula of described rosmarinic acid: C 18h 16o 8, molecular weight: 360.31, structure is as follows:
The molecular formula of described salvianolic acid B: C 36h 30o 16, molecular weight: 718.61, structure is as follows:
Figure FSA00000811649100021
The molecular formula of described salvianolic acid C: C 26h 20o 10, molecular weight: 492.43, structure is as follows:
Wherein said compositions is to be made by following weight proportion: salvianolic acid A 90%～99%, alkannic acid 0.1%～3%, rosmarinic acid 0.1%～3%, salvianolic acid B 0.1%～3%, salvianolic acid C 0.1%～5%.
2. purposes according to claim 1, wherein said compositions is to be made by following weight proportion: salvianolic acid A 93%～98%, alkannic acid 0.1%～2.0%, rosmarinic acid 0.1%～2.0%, salvianolic acid B 0.1%～2.0%, salvianolic acid C 0.1%～3%.
3. purposes according to claim 2, wherein said compositions is to be made by following weight proportion: salvianolic acid Δ 94%～97%, alkannic acid 0.1%～1.5%, rosmarinic acid 0.1%～1.5%, salvianolic acid B 0.1%～1.5%, salvianolic acid C 0.1%～2.0%.
4. purposes according to claim 3, wherein said compositions is to be made by following weight proportion: salvianolic acid A 95%～96%, alkannic acid 0.1%～1.2%, rosmarinic acid 0.1%～1.2%, salvianolic acid B 0.1%～1.2%, salvianolic acid C 0.1%～1.5%.
5. purposes according to claim 1, wherein said compositions adopts following steps to prepare:
(1) extract: Radix Salviae Miltiorrhizae water or alcoholic solution extract and obtain aqueous extract or alcohol extract;
(2) transform: the extracting solution that step (1) is obtained, adjust pH to 3.5～6.5, add the catalyst that molar percentage is 0.1%～3.0%, 100～140 ℃ of heating 1～6 hour;
(3) purification:
A. solution step (2) obtained, adjust pH to 2.5～4.5, centrifugal, and supernatant separates through nonpolar or low pole macroporous resin column chromatography, after washing with water, uses the eluant eluting, and high performance liquid chromatogram detects salvianolic acid A, collects the eluent that contains salvianolic acid A;
B. sephadex lh-20 or ODS-C18 or the separation of polyamide chromatography post for eluent step a obtained, use the eluant eluting, and high performance liquid chromatogram detects salvianolic acid A, collects the eluent that contains salvianolic acid A;
C. eluent step b obtained is adjusted pH to 2.0～4.0, through organic solvent extraction, and the Separation of Organic phase;
D. solution step c obtained separates with silica gel column chromatography, uses the eluant eluting, and high performance liquid chromatogram detects salvianolic acid A, collects the eluent that contains salvianolic acid A;
(4) drying: the eluent that steps d is obtained, the reclaim under reduced pressure eluant, then be dissolved in water, with vacuum drying, spray drying or microwave vacuum drying, obtain described salvianolic acid A compositions.
6. purposes according to claim 5, it is characterized in that the water extracting method described in step (1) is: get red rooted salvia, be cut into decoction pieces or be ground into diameter 2mm granule, add 3～15 times of water gagings at every turn and extract, extract altogether 1～3 time, extract 1～4 hour at every turn; Extracting solution is evaporated to relative density 1.10～1.25 (60 ℃), add ethanol to make containing the alcohol amount 30%～80%, centrifugal, the supernatant decompression recycling ethanol also is concentrated into without the alcohol flavor, described water extraction adopts decoction to extract or 45～95 ℃ of water temperature lixiviates are got, stir with 10～50 rev/mins of speed simultaneously, obtain Radix Salviae Miltiorrhizae extract.
7. purposes according to claim 5, it is characterized in that the alcohol extraction method described in step (1) is: get red rooted salvia, be cut into decoction pieces or be ground into diameter 2mm granule, add 3～15 times of amount 30%～60% alcohol reflux at every turn, the each extraction 1～4 hour, extract 1～3 time altogether; Decompression recycling ethanol, obtain Radix Salviae Miltiorrhizae extract.
8. purposes according to claim 5, wherein in the extracting solution in step (1), salvianolic acid B concentration is 1mg/ml～30mg/ml or is diluted with water to 1mg/ml～30mg/ml.
9. purposes according to claim 8, wherein in extracting solution, salvianolic acid B concentration is 5mg/ml～20mg/ml or is diluted with water to 5mg/ml～20mg/ml.
10. purposes according to claim 5, wherein the catalyst in step (2) is one or more in iron chloride, ruthenium trichloride, aluminum chloride, zinc chloride, Palladous chloride., the molar percentage of catalyst and salvianolic acid B is 0.1%～3.O%.
11. purposes according to claim 10, wherein the molar percentage of catalyst and salvianolic acid B is 0.5%～2.0%.
12. purposes according to claim 5, is characterized in that macroporous resin column described in step a is HPD-80, HPD-100, HPD-100B, HPD-200A, HPD-300, HPD-450, HPD-722, HPD-826, ADS-5, ADS-8, ADS-21 or D101, AB-8; The water that described eluant is water and different proportion and ethanol, and first water, 10～40% ethanol elutions, then use 20～60% ethanol elutions, high performance liquid chromatogram detects salvianolic acid A, collects and contains the salvianolic acid A part, and eluent is concentrated into without the alcohol flavor.
13. purposes according to claim 5, it is characterized in that water and ethanol that the described eluant in step b is water and different proportion, and first water, 20～60% alcoholic solution eluting remove impurity, use again 40～90% alcoholic solution eluting, high performance liquid chromatogram detects salvianolic acid A, collection contains the salvianolic acid A part, and eluent is concentrated into without the alcohol flavor.
14. purposes according to claim 5, is characterized in that the organic solvent described in step c is t-butyl methyl ether, methyl acetate, ethyl acetate, butyl acetate or Ethyl formate.
15. purposes according to claim 5, is characterized in that the two-phase solvent that eluant described in steps d is petroleum ether, pentane, normal heptane, ethyl acetate, methyl acetate, Ethyl formate, t-butyl methyl ether composition.
16. purposes according to claim 5, is characterized in that the temperature of microwave vacuum drying described in step (4): 20-100 ℃, return difference temperature 1-5 ℃, and more than vacuum-0.07Mpa, microwave power 1-100KW, dry 10-200 minute.
17. purposes according to claim 5 is characterized in that vacuum drying temperature described in step (4): 50 ℃～90 ℃, more than vacuum-0.07Mpa, power: 1～60KW, dry 2～20 hours.
18. purposes according to claim 5 is characterized in that spray-dired intake air temperature described in step (4): 150 ℃～350 ℃, the air outlet temperature: 70 ℃～95 ℃, spray velocity: 1～300ml/min.
19. purposes according to claim 5, is characterized in that pH adjusting agent is phosphoric acid, hydrochloric acid, sulphuric acid or acetic acid.
20. purposes according to claim 1, wherein said compositions adopts the high effective liquid chromatography for measuring salvianolic acid A, alkannic acid, and rosmarinic acid, salvianolic acid B, salvianolic acid C content, condition determination is as follows:
Take octadecylsilane chemically bonded silica as filler;
Detect wavelength 286nm; Flow velocity 1.0ml/min; 30 ℃ of column temperatures;
Theoretical cam curve should be not less than 10000 by salvianolic acid A;
The preparation precision of reference substance solution takes salvianolic acid A, alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C reference substance in right amount to volumetric flask, adds methanol and makes the mixing reference substance solution;
The preparation of need testing solution: precision takes sample 10mg in the 100ml volumetric flask, adds dissolve with methanol and shakes up, and be diluted to scale, obtains;
Eluting be take methanol as mobile phase A, take 0.1～0.5% phosphoric acid as Mobile phase B, by following condition, carries out gradient elution, moves 60 minutes;
In the time of 0～10 minute, the ratio of methanol is down to 60% by 30% ratio that rises to 40%, 0.1～0.5% phosphate aqueous solution by 70%;
In the time of 10～30 minutes, the ratio of methanol is down to 45% by 40% ratio that rises to 55%, 0.1～0.5% phosphate aqueous solution by 50%;
In the time of 30～60 minutes, the ratio of methanol is down to 20% by 55% ratio that rises to 80%, 0.1～0.5% phosphate aqueous solution by 45%;
Algoscopy: the accurate persorption of inhaling closes reference substance solution and each 10 μ l of need testing solution respectively, and the injection liquid chromatography, measure, and calculates the content of salvianolic acid A, alkannic acid, rosmarinic acid, salvianolic acid B, salvianolic acid C.
21. according to the purposes of claim 1, wherein said for the prevention and the treatment ischemic heart desease disease comprise following one or more: coronary heart diseases and angina pectoris, ischemic cardiomyopathy, myocardial infarction, myocardial ischemia apoplexy, acute coronary syndrome, coronary stricture, myocardial ischemia reperfusion injury, atherosclerosis.
22., according to the purposes of claim 1 or 21, wherein said salvianolic acid A compositions is for improving the hemodynamic purposes of Ischemic Heart.
23., according to the purposes of claim 22, wherein said salvianolic acid A compositions is for improving the purposes of ischemic heart cardiac function.
24., according to the purposes of claim 22, wherein said salvianolic acid A compositions is for increasing the purposes of the coronary flow of ischemic heart.
25., according to the purposes of claim 1 or 21, wherein said salvianolic acid A compositions is for reducing the purposes of ischemic heart myocardial infarct size.
26., according to the purposes of claim 25, wherein said salvianolic acid A compositions is for dwindling the purposes of myocardial ischemia scope.
27., according to the purposes of claim 25, wherein said salvianolic acid A compositions is for alleviating the purposes of degree of myocardial ischemia.
28., according to the purposes of claim 25, wherein said salvianolic acid A compositions is regulated the purposes of Enzyme Activities for the protection of the myocardial cell membrane structure.
29., according to the purposes of claim 25, wherein said salvianolic acid A compositions is for suppressing the purposes of ischemic myocardial tissue inflammatory reaction.
30., according to the purposes of claim 25, wherein said salvianolic acid A compositions is for the protection of the purposes of myocardial mitochondria damage.
31., according to the purposes of claim 1 or 21, wherein said salvianolic acid A compositions is for improving the purposes of myocardial metabolism.
32., according to the purposes of claim 31, wherein said salvianolic acid A compositions comprises for improving one or more of following myocardial metabolism for the purposes of improving myocardial metabolism: myocardium radical metabolism, fatty acid metabolism, energy metabolism.
33., according to the purposes of claim 1 or 21, wherein said salvianolic acid A compositions is for reducing the purposes of myocardial oxygen consumption.
34., according to the purposes of claim 1 or 21, wherein said salvianolic acid A compositions is for improving hemorheological purposes.
35., according to the purposes of claim 1 or 21, wherein said salvianolic acid A compositions is for suppressing thrombotic purposes.
CN201210487255.6A 2012-11-20 2012-11-20 A kind of salvianolic acid A compositions and prepare medicinal usage Active CN103142577B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210487255.6A CN103142577B (en) 2012-11-20 2012-11-20 A kind of salvianolic acid A compositions and prepare medicinal usage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210487255.6A CN103142577B (en) 2012-11-20 2012-11-20 A kind of salvianolic acid A compositions and prepare medicinal usage

Publications (2)

Publication Number Publication Date
CN103142577A true CN103142577A (en) 2013-06-12
CN103142577B CN103142577B (en) 2016-01-06

Family

ID=48541092

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210487255.6A Active CN103142577B (en) 2012-11-20 2012-11-20 A kind of salvianolic acid A compositions and prepare medicinal usage

Country Status (1)

Country Link
CN (1) CN103142577B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083298A (en) * 2012-11-20 2013-05-08 蒋春红 Application of salvianolic acid A composition in preparing medicines for protecting ischemic brain tissue damage
CN103083296A (en) * 2012-11-20 2013-05-08 蒋春红 Application of salvianolic acid A composition in preparing medicines for protecting cerebrovascular endothelial cells
CN103083297A (en) * 2012-11-20 2013-05-08 蒋春红 Application of salvianolic acid A composition in preparing medicines for improving neural function symptom after cerebral ischemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999470A (en) * 2006-11-17 2007-07-18 北京本草天源药物研究院 Salvia minium phenolic acid A and process of preparing preparation and use
CN102212004A (en) * 2010-04-06 2011-10-12 山东靶点药物研究有限公司 Method for preparing salvianolic acid A by catalytically converting salvianolic acid B
CN102210666A (en) * 2010-04-06 2011-10-12 山东靶点药物研究有限公司 Medical use of salvianolic acid A

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999470A (en) * 2006-11-17 2007-07-18 北京本草天源药物研究院 Salvia minium phenolic acid A and process of preparing preparation and use
CN102212004A (en) * 2010-04-06 2011-10-12 山东靶点药物研究有限公司 Method for preparing salvianolic acid A by catalytically converting salvianolic acid B
CN102210666A (en) * 2010-04-06 2011-10-12 山东靶点药物研究有限公司 Medical use of salvianolic acid A

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083298A (en) * 2012-11-20 2013-05-08 蒋春红 Application of salvianolic acid A composition in preparing medicines for protecting ischemic brain tissue damage
CN103083296A (en) * 2012-11-20 2013-05-08 蒋春红 Application of salvianolic acid A composition in preparing medicines for protecting cerebrovascular endothelial cells
CN103083297A (en) * 2012-11-20 2013-05-08 蒋春红 Application of salvianolic acid A composition in preparing medicines for improving neural function symptom after cerebral ischemia

Also Published As

Publication number Publication date
CN103142577B (en) 2016-01-06

Similar Documents

Publication Publication Date Title
CN1931236B (en) Medicine composition of red sage and rhodiola root
CN103142577B (en) A kind of salvianolic acid A compositions and prepare medicinal usage
CN103142571B (en) A kind of salvianolic acid A compositions and prepare medicinal usage
CN103083297A (en) Application of salvianolic acid A composition in preparing medicines for improving neural function symptom after cerebral ischemia
CN103142516B (en) A kind of salvianolic acid A drop pill and prepare medicinal usage
CN103142572B (en) A kind of salvianolic acid A tablet and prepare medicinal usage
CN103083298B (en) Salvianolic acid A compositions is for the preparation of the purposes of protection ischemic tissue of brain damage medicine
CN103099802B (en) Salvianolic acid A compositions is for the preparation of the purposes saving cerebral ischemic penumbra medicine
CN103083301B (en) Salvianolic acid A compositions is for the preparation of prevention and or the purposes for the treatment of cerebral thrombosis medicine
CN103142579B (en) A kind of salvianolic acid A freeze-dried powder and prepare medicinal usage
CN102973544B (en) Salvianolic acid A lyophilized powder and application thereof in preparing medicaments
CN103142543B (en) A kind of salvianolic acid A capsule and prepare medicinal usage
CN103142578B (en) A kind of salvianolic acid A freeze-dried powder and prepare medicinal usage
CN103665180A (en) Application of Morindae officinalis oligosaccharide 6 glycan in preparation of myocardial ischemia and reperfusion injury resistance medicines
CN102988307B (en) A kind of salvianolic acid A freeze-dried powder and prepare medicinal usage
CN103142542B (en) A kind of salvianolic acid A capsule and prepare medicinal usage
CN103083296A (en) Application of salvianolic acid A composition in preparing medicines for protecting cerebrovascular endothelial cells
CN103142517B (en) A kind of salvianolic acid A drop pill and prepare medicinal usage
CN103120656B (en) Danshinolic acid A tablet and application thereof for preparing medicines
CN101084965A (en) Safflower compound preparation and its preparation technology
CN103006579B (en) Application of salvianolic acid A lyophilized powder injection in preparation of drugs for protecting cerebrovascular endothelial cells
CN103006581B (en) Application of salvianolic acid A lyophilized powder injection in preparation of drugs for treating ischemic penumbra
CN103006578B (en) Application of salvianolic acid A lyophilized powder injection in preparation of drugs for improving neurological function symptoms after cerebral ischemia
CN103006580B (en) Application of salvianolic acid A lyophilized powder injection in preparation of drugs for preventing and/or treating cerebral thrombosis
CN103301104A (en) Use of danshinolic acid A composition in preparing ischemic penumbra treatment medicaments

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151126

Address after: 341000 East Road, Shahe Industrial Park, Jiangxi, Ganzhou, No. 8

Applicant after: Jiangxi Qingfeng Pharmaceutical Co., Ltd.

Address before: 570105 Hainan Province, Haikou City Binhai Avenue Road, Xiuying District Court 13-D Regent Bay South

Applicant before: Chen Feihong

C14 Grant of patent or utility model
GR01 Patent grant